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We have used a 3D age-scalable computational phantom for over two decades for 
retrospective dose reconstruction studies of childhood cancer survivors (CCS) treated with 2D 
historic radiotherapy (RT). However, our phantom and its age scaling functions (ASF) must be 
updated so that it can be used in studies that include survivors treated with contemporary 
RT. We aimed to implement our phantom and its age scaling functions in DICOM format and 
determine the feasibility of applying our ASFs to accurately scale the whole-body CT-based 
anatomies. 
In the implementation study, we developed Python scripts that model the phantom 
and ASFs in a treatment planning system (TPS). We validated the implementation by 
comparing several geometric and anthropometric parameters with reference datasets. We 
then conducted a dosimetric analysis to determine the accuracy of dose calculation using our 
phantom. In the feasibility study, we downscaled various computed tomography (CT)-based 
vii 
 
phantoms from the University of Florida/National Cancer Institute (UF/NCI) phantom library 
to arbitrary ages. We quantified the geometric accuracy of scaling by comparing several 
overlaps, distance, and anthropometric parameters of the scaled phantom with reference 
datasets. We also assessed the dosimetric impact of ASFs by quantifying the difference in 
dose from standard Wilms’ tumor RT plan simulated on exact age-scaled and nearest age-
matched phantom while using the same field size and anatomical landmark dependent field 
size in two different scenarios.  
This study showed that phantoms were implemented in DICOM format within 3% of 
points/volume of our original phantoms. The heights and dosimetric accuracy were within 7% 
of ground-truth values. In the feasibility study, overlap metrics showed “good” agreement for 
most cases except pancreas and kidneys. The maximum displacement of 4.1cm was obtained 
in the scaled liver. In both implementation and feasibility studies, organ masses were smaller 
than reference masses in general. A difference of 6% and 1.3Gy was obtained for percent 
volume ≥ 15Gy (V15) and mean dose, respectively, across two phantom categories when the 
same field size was used. Both metrics were significantly different (p<0.05) for partially in-
beam organs when field size varied. Overall, our results show that phantom and ASFs can be 
accurately used in TPS for modern RT studies, and our ASFs can accurately scale whole-body 
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Chapter 1: Introduction 
1. Background to the Problem 
The advancements of radiation therapy (RT) treatment techniques have increased the 
survival rate of cancer patients over the last few decades, however, RT modalities are 
associated with dose to non-target organs/organs at risk (OAR) at the same time (Kry et al 
2017). The dose to OARs depends on the proximity of the organ to the target volume. Organs 
that are completely in-beam or partially in-beam receive varying degrees of unwanted 
radiation, largely depending on their proximity to the target volume. Organs that are entirely 
out of beam receive lesser amounts of unwanted radiation due to stray radiation originating 
from linac head leakage, collimator scatters, and patient scatters (Kry et al 2017, Xu et al 
2008). The dose received by these OARs increases the risk of developing early and late 
effects/toxicity in these organs (Kry et al 2017). It has been estimated that 1% of the cancer 
survivors will develop RT-related subsequent neoplasm (SNM), which corresponds to 
approximately 150,000 patients (De Gonzalez et al 2011).  In the case of childhood cancer 
survivors (CCS) treated with radiation therapy (RT), the survivors are at higher risk to develop 
late effects as they have greater tissue sensitivity to radiation (Kutanzi et al 2016), a longer 
life expectancy, and a greater survival rate than an adult (Armstrong et al 2016, Turcotte et al 
2017, Gibson et al 2018).  
1.1 RT epidemiologic studies 
The risk of developing late effects is investigated in radiation epidemiologic studies (also 
known as late effects studies) where doses from RT to OARs are correlated with late effects in 
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those organs in long-term cancer survivors. Because late effects occur years and often 
decades after treatment, survivor cohorts often include survivors treated in the pre-
computed tomography era of RT. Thus, organ doses are not available in their historic RT 
records and must be reconstructed in retrospect using surrogate anatomy. This is typically 
done using established dose reconstruction methods (Stovall et al 2006, Howell et al 2019), 
briefly summarized here.  
We first begin by abstracting RT treatment plan from the cancer survivor cohort 
(N>10,000), and then we reconstruct RT fields on surrogate anatomy to estimate dose to 
OARs (Stovall et al 2006, Howell et al 2019). The abstraction usually involves coding of 
anthropometric parametric and RT plans of the survivor. If the cohorts include survivors 
treated in the pre-CT era, then parameters such as age, height and weight (sporadically 
available), sex, date, prescription dose, beam energy, orientation, field size, anatomical 
landmarks, and organs proximity to the fields are available (Howell et al 2019). These 
parameters are used to reconstruct the dose on the surrogate anatomy. If the cohort 
includes survivors treated with contemporary RT such as 3D conformal RT, intensity, 
volumetric modulated RT (IMRT and VMAT) and particle therapy, then a survivor CT scan with 
an RT plan is available. However, partial CT scans are available in most cases where 
information is limited to anatomy near the target volume. Therefore, surrogate anatomy for 
missing organs/body regions is combined with a partial CT scan to estimate the organ dose. 
Since doses are reconstructed in retrospect in both cases, the success of such studies is 
heavily dependent on the accuracy, suitability, and efficacy of dose reconstruction methods 
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and the type of surrogate anatomy used in the studies as associated uncertainty could result 
in a large error in risk assessments (Xu et al 2008, Vũ Bezin et al 2017).  
There are two major approaches that are used to reconstruct organ doses from the stray 
radiation: (1) anthropometric phantom approach, (2) computational approaches (Stovall et al 
2006, Howell et al 2019, Kry et al 2017, Xu et al 2008). In the anthropometric phantom 
approach, organ doses are measured using phantoms such as Alderson RANDO phantoms 
which consist of contiguous plastic slabs of tissue equivalent materials for varying the shape 
and the size. The dosimeters such as Thermoluminiscents detectors (TLD) are placed at 
different distances and depths, and the phantoms are irradiated using treatment parameters 
to estimate the dose (Stovall et al 2006). There exist several limitations that preclude its use 
in large cohorts of cancer survivors. First of all, the anthropometrics phantoms are limited to 
specific ages, and the phantom slabs have limited thickness and number per body region, 
limiting the variation in shape. Further, it is not feasible to perform the physical experiments 
using phantoms for all survivors in large cohorts. In computational approaches, a treatment 
planning system (TPS) can be used to estimate in-beam or partially in-beam organ dose, but 
the accuracy decreases as the distance between out-of-field organ and main treatment field 
increases (Kry et al 2017). It has been found that TPS exhibits up to 30% error in organ doses 
that are 3cm from the field edges (Howell et al 2010b). The Monte Carlo methods are one of 
the feasible options in which different treatment scenarios and patient geometrical models 
can be simulated. However, the models must be validated with the machines used for 
treatment (Kry et al 2017) which is not feasible to conduct for each survivor in large cohorts. 
Considering the limitations mentioned above, the most viable option for large cohorts is 
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analytical dose calculation models combined with 3D computational phantoms. The analytical 
models consist of mathematical formulation and measurement data for different field sizes, 
beam energy, depth, orientation, etc., which are used when RT fields are reconstructed on 
computational phantoms to reconstruct dose to OARs (Stovall et al 2006, Howell et al 2019, 
Kry et al 2017). 
1.2 Computational phantoms 
There are different categories of computational phantoms that have the potential for use 
in late effects studies. The first and the simplest class is stylized phantoms which is also the 
most widely used phantom type for CCS treated in the pre-CT era (Howell et al 2019). Stylized 
phantoms consist of simple geometrical shapes that represent organs and body regions (Xu 
2014). The geometrical structures are described by quadratic equations, allowing them to be 
scaled to match various anthropometric parameters (Kry et al 2017, Zaidi and Tsui 2009, Xu 
2014). However, the main limitation of these phantoms is the deviation from realistic and 
complex human anatomy, which could introduce uncertainty in organ dose estimation if the 
dose reconstruction method relies on the organ shape. The anatomical realism has been 
addressed up to an appreciable extent in the next category known as Voxel phantoms. In this 
type, the voxels defining organs and body regions are obtained by segmenting patient 
CT/MRI scans (Lee et al 2010, Zaidi and Tsui 2009, Xu 2014). Voxels defining a particular 
organ are given the same identification numbers. Although voxel phantoms are anatomically 
more realistic than stylized phantoms, they cannot be scaled to different heights, ages, 
weights, etc., which results in errors up to 150% in some cases when used instead of stylized 
phantoms (Kry et al 2017, Lee et al 2006). The most advanced and most realistic category of 
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the phantom is hybrid phantoms which combine anatomical realism of voxel phantoms with 
the mathematical surface equations of the stylized phantoms (Bolch et al 2010). There are 
several hybrid phantom libraries which include reference size, body-size dependent (height 
and weight dependent), patient-specific, and percentile-specific phantoms and can be scaled 
to match various anthropometric parameters but the time required to scale each phantom 
ranges up to 20 minutes which could result in the longer calculation time for large cohorts. 
Another limitation is that phantoms are available at discrete ages (e.g. newborn, 1, 5, 10, 15, 
adult) or at discrete heights or discrete weights due to which nearest available age or height 
or weight are used when the phantom of exact parameter for survivors is unavailable. The 
could result in uncertainty organ dose and risk-assessment studies. 
2. MD Anderson Late Effects Group Computational Phantoms and Statement of the Problem 
The Radiation Dosimetry Service (RDS) at UT MD Anderson Cancer Center developed a 3D 
age-scalable computational phantom over three decades ago, which has been used in more 
than 120 studies for retrospective dose reconstruction of CCS treated with 2D RT plans 
(Howell et al 2019). This phantom was modeled initially in FORTRAN and can be scaled to any 
arbitrary age using non-uniform body region-specific 3D age-scaling functions (ASFs). The 
phantom consists of 5 rectangular cuboids representing the head, neck, trunk, legs, arms, 
body regions, and over 20 organs. Each body region and organ is represented by 3D points, 
and doses are predicted by calculating the dose to individual points using several 
reconstruction methods as described by Stovall et al (2006) and Howell et al (2019). The 
availability of robust and fast age-scaling methodologies makes this phantom suitable for the 
dose reconstruction studies of large retrospective cohorts. 
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The modern cohorts of CCS are treated with contemporary RT modalities such as 3D CRT, 
IMRT, and VMAT, where survivor's treatment plans are present in Digital Imaging and 
Communication in Medicine (DICOM) Standard CT images. In most cases, the survivors have 
partial CT scans that only span the anatomy in the proximity of the target volume.  To 
estimate dose to organs that are not present in the CT image, one must calculate dose 
retrospectively using the alternative dose reconstruction methods as TPS calculated doses 
are inaccurate for out-of-field organs. Furthermore, in some longitudinal studies, whole-body 
CT scans of survivors could be available, which will need to be downscaled and fused with a 
partial CT scan of the survivor at different timepoints. Our dose reconstruction method and 
computational infrastructure can accurately estimate dose in the previously mentioned 
cases, provided that the computational phantom and its ASFs are accurately implemented in 
the DICOM format. 
3. Project Objective 
The overall objective of this project was to make our phantom and its ASFs compatible 
with survivors treated with modern RT and determine the feasibility and accuracy of scaling 
whole-body CT-based anatomies using our ASFs. Specifically, we first aimed to implement 
and validate our phantom and its ASFs in DICOM format. Secondly, we implemented and 
validated our ASFs to determine the feasibility of scaling whole-body CT-based anatomy to 
any arbitrary age. The implementation mentioned above, and validation will allow us to use 
our computational phantoms for cohorts treated with contemporary RT and the ASFs to scale 




4. Organization of the Thesis 
In Chapter 2 of the thesis, the details about the hypothesis, specific aims, and the projects 
within each aim are presented. In chapter 3, the implementation and validation of our 
computational phantom in the DICOM format are discussed. In chapter 4, the feasibility of 
scaling whole-body CT-based anatomy is discussed. In chapter 5, the general overview and 
future direction of the project are presented. In appendix A, the mathematical theory of 
scaling our computational phantom to 7.0-year-old is presented. In appendix B, the scaling of 
the arbitrary computational phantom using our ASFs through a graphical user interface (GUI) 
in the commercial treatment planning system is presented.  
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Chapter 2: Central Hypothesis and Specific Aims  
1. Central Hypothesis 
The central hypothesis of this thesis is that we can accurately convert our current 
phantom and its ASFs to DICOM format (within 3%) in a commercial TPS with the ability to 
scale our phantom and any CT based anatomy to any arbitrary age, i.e., infant through adult 
such that the phantom height across the age range agrees within 7% of the reference height 
data 
2. Specific Aim 1: Implementation and Validation in the DICOM Format 
Aim: Implement the phantom in DICOM format and establish the geometric accuracy in 
modeling of body regions and organs 
Hypothesis: The computational phantom can be modeled in DICOM format within ± 3% of 
the FORTRAN phantom 
Project 1.1: Develop a python script to implement the baseline FORTRAN phantom and its 
ASFs in DICOM format within TPS 
Project 1.2: Validate the phantoms in DICOM format with FORTRAN phantom and reference 
data from Center for Disease Control and Prevention, and International Commission on 
Radiological Protection 89 report 
Project 1.3: Investigate the feasibility of using phantom in DICOM format for dose calculation 
in commercial TPS and validate the organ dose with in-house dose calculation software 
Specific Aim 1 is fully addressed in chapter 3: Development of an age-scalable 3D 
computational phantom in the DICOM format 
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3. Specific Aim 2: Feasibility of Scaling CT-Based Anatomy to Arbitrary Ages 
Aim: Apply ASFs to scale the whole-body CT based anatomy to any arbitrary ages and 
validate scaling with ground-truth anatomy and reference data 
Hypothesis: The ASFs can be used to scale whole-body CT-based anatomy to any arbitrary 
ages age within 7% of the CDC reported reference height. The Dice similarity coefficient (DSC) 
and mean distance agreement (MDA) of the scaled and ground-truth anatomy are within ≥
70% and within 5cm, respectively. 
Project 2.1: Develop a python script to classify the whole-body CT based anatomy to head, 
neck, trunk, and leg body regions 
Project 2.2: Apply the ASFs to scale whole-body CT based anatomy to any arbitrary age 
Project 2.3: Validate the scaled anatomy with ground-truth anatomy and reference data from 
CDC and ICRP 89 
Project 2.4: Apply ASFs to conduct a dose study to determine the difference in organ doses of 
exact age-scaled versus nearest age-matched phantoms 
Specific Aim 2 is fully addressed in chapter 4: Scaling of whole-body computed tomography-




Chapter 3: Development of an Age-Scalable 3D Computational 
Phantom in the DICOM Format 
This chapter is based on the following peer-reviewed publication: 
A.C. Gupta, S. Shrestha, C.A. Owens, S.A. Smith, Y. Qiao, R.E. Weathers., P.A. Balter, S.F. Kry, 
and R.M. Howell, “Development of an age-scalable 3D computational phantom in DICOM 
standard for late effects studies of childhood cancer survivors,” Biomedical Physics and 
Engineering Express. Volume 6, Issue 6, pages 1-15. © IOP Publishing Ltd. 
This work is licensed under a Creative Commons Attribution 4.0 license. It is attributed to 
Aashish C. Gupta, Suman Shrestha, Constance A. Owens, Susan A. Smith, Ying Qiao, Rita E. 
Weathers., Peter A. Balter, Stephen F. Kry, and Rebecca M. Howell, and the original version 
can be found here. 
 This chapter describes the results of Specific Aim 1: Implement the phantom in 
DICOM format and establish the geometric accuracy in modeling of body regions and organs 
1. Introduction 
As mentioned in chapter 1, cancer survivors whose treatment included radiation therapy 
(RT) are at risk for developing RT-related late effects (≥5 years after diagnosis) (Travis et al 
2011). Survivors of childhood cancer are at particularly high risk because of high survival rates 
(>84%) and long-life expectancy (Armstrong et al 2016, Turcotte et al 2017, Gibson et al 
2018, Howlader et al 2019). Retrospective epidemiologic studies of cancer survivor cohorts 
investigate the relationship between RT dose to specific organs or body regions and the risk 
of subsequent late effects (Travis et al 2011). Such studies typically use computational 
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phantoms to retrospectively reconstruct doses throughout patients' bodies (Lee et al 2010, 
Travis et al 2011, Xie and Zaidi 2014, Howell et al 2019) by recomputing the radiation field 
doses on a phantom. For cohorts that include survivors of childhood cancers, phantoms 
should be scalable to the age or size of the patient at the time of RT. 
For over two decades (>120 studies), the MD Anderson Late Effects Group has used an 
age-scalable computational phantom to reconstruct dose to organs throughout the body for 
large cohorts of childhood cancer survivors treated with conventional two-dimensional (2D) 
historic RT (Howell et al 2019). This phantom is currently coded in the FORTRAN 95 
programming language and can only be used with co-planar beam geometries, which were 
standard in 2D planning. Furthermore, its current format does not support instantaneous or 
three-dimensional (3D) visualization. These limitations were acceptable for previous studies 
with cohorts treated with historic 2D RT. However, cancer survivors now include individuals 
treated with contemporary RT, e.g., 3D conformal RT, intensity- and volumetric-modulated 
RT, and particle therapy. For these individuals, complex treatment plans were designed using 
patients' computed tomography (CT) images within commercial treatment planning systems 
(TPS). Unlike in the 2D treatment planning era, dose to organs near the target volume are 
readily calculable as part of the treatment plans and therefore, will not need to be 
retrospectively recalculated. However, doses to distant organs will still need to be 
retrospectively reconstructed on computational phantoms, because CT images used for 
treatment planning may not be available for epidemiologic studies, and even if they are, the 
CT data will be limited to anatomy near the target volume and will not include distant 
structures that are typically of interest in such epidemiologic studies. 
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For retrospective whole-body dose reconstructions, the 'missing' anatomy could be 
supplemented by registering a patient's planning CT(s) with a computational phantom scaled 
to the age at RT. The MD Anderson Late Effects Group computational phantom is well suited 
for this purpose because (1) it is the most widely used phantom for late effects studies of 
historic RT and using this same phantom for studies involving contemporary RT will facilitate 
direct comparison of results between historic and modern studies; and (2) it can be uniquely 
scaled to any arbitrary age or height whereas other computational phantoms are limited to 
specific selected ages. However, the MD Anderson Late Effects Group computational 
phantom is programmed in FORTRAN language, which is not compatible for registration with 
patients' Digital Imaging and Communications in Medicine (DICOM) format CT images in 
commercial TPSs. Therefore, the primary objective of this study was to adapt the current 
model of our age-scalable computational phantom from the FORTRAN language to DICOM 
format for use within any commercial TPS, thereby facilitating epidemiologic studies of 
contemporary radiotherapy. Additionally, we report a detailed description of our age-based 
scaling functions, information that was not reported in our previous publications. Note that 
hereafter, we use phantom, FORTRAN, and DICOM for computational phantom, FORTRAN 
language, and DICOM format, respectively. 
2. Methods 
2.1 Phantom modeled in FORTRAN language (baseline phantom description) 
The MD Anderson Late Effects Group phantom was previously described by Howell et al 
(2019) and Stovall et al (2006). The phantom was built by bounding the body regions, i.e., 
head, neck, trunk, arms, and legs, of a generic gender-neutral adult skeleton (age = 18 years) 
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by cuboids, which were then fit to a 3D grid of evenly spaced points (Figure 1). Each cuboid is 
defined by its eight corner points obtained from its fit to the 3D grid. Various organs are 
defined within the phantom's body regions as grids of points (Howell et al 2019). 
 
 
Figure 1: Diagrams of our computational phantom fitted to a 3D grid of points. (a) coronal 
view showing +x and –y axes and (b) sagittal view showing –y and –z axes. A skeleton is 
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overlaid on the phantom for anatomic reference. The scalable body regions (head, neck, 
trunk, and extremities) are delineated in frontal view. 
2.2 Scaling functions 
Because this phantom was intended for use in late effects studies of cancer survivors, 
including children, whose ages at the time of their RT ranged from infant to adult, it was 
necessary to define scaling functions to adapt the generic adult phantom (18 years of age) to 
any age. The head, neck, trunk, and extremities of the human body undergo non-uniform 
growth from infant to adulthood. For example, at birth the human head makes up 
approximately one quarter of the total height, but that proportion decreases to about one-
seventh by adulthood (Huelke 1998). This non-uniform growth was quantitatively reported by 
the Society of Automotive Engineers based on measurements of 4127 US infants, children 
and youths through 18 years old (Snyder et al 1977). As a function of age, using these growth 
data, we plotted sizes of the head, neck, trunk, and extremities (legs and arms) in three 
dimensions (Figure 2). Then, we calculated the discrete scaling factor, Fdis, by taking the ratio 
of the size of a specified body region r in a specified direction d at a given age a to its size in 
the generic phantom, equation (1). 






d ∈ {Left to right (x), superior to inferior (y), anterior to posterior (z)} 
r ∈ {upper head (uh), lower head (lh), neck (n), trunk (tr), arms (ar), legs (lg)} 
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a ∈ {0.1 (1 month), 1, 3, 5, 10, 15, 18} and  
g is a constant and is defined as age 18 years; the age of the generic phantom 
Since equation (1) can only be used for scaling to discrete ages of 0.1 (1 month), 1, 3, 5, 10, 
15, and 18 years, to allow scaling between these ages, we created age intervals of [0, 1), [1, 
3), [3, 5), [5, 10), [10, 15), and [15, 18) and defined a continuous scaling function, for each age 
interval (equation (2)). 
Fcont(d, r, a) = Fdis(d, r, a−) +
a − a−
a+ − a− 
(Fdis(d, r, a+) − Fdis(d, r, a−)) 
2 
Where a− and a+ are lower and upper age bounds, respectively. Each organ was considered 




Figure 2: (A)–(E) Growth as a function of age from superior to inferior, left to right, and 
anterior to posterior for the head, neck, trunk, arms and legs for ages 1 month, 1, 3, 5, 10, 15, 
and 18 (adult) years (Snyder et al 1977, Huelke 1998). 
2.3 Transformation functions 
17 
 
Each body region is represented by eight corner points and each organ is represented by 
a grid of points, where each point (P) is a set of three real numbers (coordinates) denoted by 
the variables 𝑥, 𝑦, and 𝑧, which represent the coordinates of a point. Once the necessary 
scaling factors are obtained using the scaling functions from section 2.2, we can apply these 
factors to each body region corner point and each organ point to transform them to various 
ages. Additionally, in the 𝑦 and 𝑧 directions, translations are also necessary so that all body 
regions remain contiguous and do not overlap as they scale; they are applied as described in 
the following paragraphs. 
Since the generic phantom is symmetric about the x-axis (Figure 1), the transformed x-
coordinate 𝑥𝑡 can be obtained by taking the product of the continuous scaling factor (𝐹𝑐𝑜𝑛𝑡) 
and the x-coordinate (𝑥), equation (3). 
𝑥𝑡 =  𝑥 ·  𝐹𝑐𝑜𝑛𝑡(𝑥, 𝑟, 𝑎) 3 
Conversely, the generic phantom is asymmetric about the y-axis and starts at the 𝑥 − 𝑧 plane 
where 𝑦 = 1 cm (Figure 1). To obtain the transformed y-coordinate (𝑦𝑡), we sum the product 
of the continuous scaling factor and the length for each body region (𝑙𝑟,𝑦) along the y-axis of 
the generic phantom, equation (4). The length of each body region along the y-axis is 
obtained by taking the difference between the inferior (𝑖𝑏𝑟) and superior (𝑠𝑏𝑟) boundaries of 
that body region in the generic phantom, i.e. 𝑦𝑖𝑏𝑟𝑟, and 𝑦𝑠𝑏𝑟𝑟, respectively. For the body 
region in which the point lies, the length is the difference between the y-coordinate (𝑦) and 
the superior boundary of that body region. 
yt = ∑ lr,y
r
r=uh
⋅ Fcont(y, r, a)  where lr,y = {
y − ysbrr ,   y ∈ r





Similarly, the generic phantom is asymmetric about the z-axis and the anterior aspect 
of each body region is at a different location in the x-y plane. Thus, to calculate a transformed 
z-coordinate (𝑧𝑡) first we calculate the difference between the z-coordinate (𝑧) and the 
anterior boundary of the body region in the z direction (𝑧𝑎𝑏𝑟𝑟). Next, we multiply this 
difference by the continuous scaling factor. Lastly, we add a (𝑧𝑠ℎ𝑖𝑓𝑡), equation (5). 
𝑧𝑡 = (𝑧 − 𝑧𝑎𝑏𝑟𝑟) ⋅ 𝐹𝑐𝑜𝑛𝑡(𝑧, 𝑟, 𝑎)  + 𝑧𝑠ℎ𝑖𝑓𝑡 5 
where zshift is described in equation (6) and differs according to the body region, 
zshift  =  




where lr,z is the length of the body region in the z direction. 
2.4 Phantom adaptation from FORTRAN to DICOM 
For this study, we used RayStation V8.99 TPS (RaySearch Laboratories, Stockholm) 
because this TPS is used in our clinic and allows addition of user-specific customized features 
via Python scripting. We developed a script in Python that converts the generic phantom 
from FORTRAN to DICOM. The conversion is a 7-step process (Figure 3), which is executed 
through a graphical user interface (GUI) scripted within the RayStation TPS. 
1. Import Data: The corner points of each body region and the points of 9 different 
organs for the generic phantom (age = 18 years) are imported from the FORTRAN 
code into RayStation. The organs that were modeled in this study are – Brain (Frontal 
Lobes (Right and Left), Temporal Lobe (Right and Left), Parietal Lobe (Right and Left), 
Cerebellum, Occipital Lobes, and Inner brain), Heart, Liver, Lungs (Right and Left), 
Stomach, Pancreas, Kidneys (Right and Left), and Thyroid Lobes (Right and Left). 
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2. Select Phantom Age: The user is then prompted to select the desired age. The user 
can select any value from 0.1 (i.e., newborn) to 18 years. Values are specified to the 
nearest tenth of a year. We assume growth stops at age 18 and for ages above 18, 
phantom is simply scaled to age 18.  
3. Transform Coordinates: Equations (1) through (6) are hardcoded into the script. Based 
on the phantom age selected in step 2, each point imported from step 1 is 
transformed using equations (1) through (6). After this step, each organ and body 
region will have been scaled to the appropriate size based on the user-selected age. 
4. Reorient Phantom: Since the coordinate systems are defined differently in the 
FORTRAN code and RayStation TPS, we apply an additional rigid transformation to 
reorient the phantom to the most common RT treatment orientation, which is head-
first supine.  
5. Convert Body Regions to DICOM format: Each body region is converted from a 
collection of vertices to a region of interest (ROI) using RayStation’s Box ROI 
generation tool (through python script). 
6. Convert Organs to DICOM format: Each organ is converted from a collection of grid 
points to an ROI using convex hull algorithm through python script.  
7. Plot Phantom in RayStation: Once each body region and organ are in DICOM format, 






Figure 3: Flow chart explaining the adaptation of the phantom to DICOM format 
Once the phantom has been generated in RayStation, users can export the phantom in 
DICOM format. This file can be uploaded into any DICOM-compatible TPS. A sample 
calculation of transformation of our generic 'adult' phantom to a 7-year-old phantom is 
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illustrated in the appendix A. Note that when we adapted our phantom from the FORTRAN to 
DICOM, we made two simplifications to the extremities: (1) the legs were simplified to 
consist of only one cuboid volume, as opposed to two separate cuboids and (2) the arm 
positions were constrained to a single position parallel to the sagittal plane (i.e. superior to 
inferior) as opposed to having variable positions of parallel or perpendicular to the sagittal 
plane of the body. 
2.5 Validation 
For this study, we performed two different validation approaches. For the first approach, 
we validated the conversion of our phantom model from FORTRAN to DICOM. To do this, we 
compared several geometric parameters between the phantom scaled to ages 1 month, 6 
months, 1, 2, 3, 5, 8, 10, 15, and 18 years modeled in FORTRAN and DICOM. For the second 
approach, we compared the heights of the DICOM model of our phantom with population 
height data from the World Health Organization (WHO) and the Centers for Disease Control 
and Prevention (CDC) (Centers for Disease Control and Prevention 2000). 
2.5.1 Comparison of FORTRAN phantom with DICOM phantom  
The first metric we calculated was the percent difference. This metric was calculated 
for all corner points in each spatial dimension of each body region and for the volumes of 
each body region between the phantom modeled in FORTRAN and DICOM. For the locations 
of the corner points, we calculated this difference in the x-, y-, and z-coordinates individually 
for each age-scaled phantom. This analysis was done for the head, neck, and trunk body 
regions, which includes the majority of organs of interest for late effects studies. Percent 








where F corresponds to the coordinates (or volume) from FORTRAN (ground-truth) and D 
corresponds to the coordinates (or volume) from DICOM for the specified body region. The 
second metric we calculated was the normalized mean square distance (NMSD). The NMSD 
was calculated between the organs (heart, liver, lungs, stomach, and brain) for both 
phantoms using the following equation. 
NMSD =






where, x, y, and z represent the coordinates of each organ point in the phantoms. The 
subscripts F and D represent that the coordinate of the point is from the FORTRAN and 
DICOM phantoms, respectively. N is the total number of points in each organ. 
The third metric we calculated was the difference in heights between the FORTRAN 
and DICOM phantoms. This was calculated to ensure that the total height of the phantom 
was preserved when converted from FORTRAN to DICOM. 
2.5.2 Comparison of DICOM phantom with WHO/CDC population height data 
In order to determine if the heights of our age-scaled phantoms were consistent with the 
heights of children across the ages of infant to adolescent, we compared our age-scaled 
phantom heights with a reference dataset. Specifically, we compared our age-scaled DICOM 
phantoms with the 50th-percentile heights reported by the WHO for ages 1 month, 6 
months, and 1 year old and with the averages of the 50th-percentile heights for males and 
females reported by the CDC for ages 2, 3, 5, 8, 10, 15, and 18 years. 
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2.6 Comparison with reference phantoms organ masses 
In FORTRAN format, organs in our phantom were modeled as grids of points, making it 
impossible to compare organ volumes or masses with other reference phantoms. In the 
updated DICOM format, such comparisons are possible and therefore were performed as 
part of this work. Specifically, we compared organ masses of the DICOM phantom with 
reference masses from International Commission on Radiological Protection (ICRP) 89 (ICRP 
2002) and University of Florida (UF)/National Cancer Institute (NCI) reference hybrid voxel 
phantoms for ages 6 days (newborn), 1, 5, 10, 15, and 18 years (Adult) (Lee et al 2010). We 
first calculated the organ masses for our DICOM phantoms (scaled to aforementioned ages) 
as a product of ICRU 46 reference densities and RayStation voxel-based volumes. The volume 
of the organs in our DICOM phantom is independent of sex but the ICRP 89 and UF/NCI 
reference phantoms provide sex dependent masses for the 15 years old and adult phantoms. 
In those cases, the average of male and female reference organ masses were calculated. 
Additionally, for the heart and stomach, the UF/NCI reference phantoms have masses for the 
wall and contents of these organs. For kidneys, the masses of the medulla, pelvis and cortex 
were reported individually. For heart, stomach and kidneys, we calculated the total mass by 
summing the mass of each organ's parts. Lastly, we computed the difference between the 
organ masses of the DICOM phantom and of the reference phantoms. 
2.7 Dose calculation with DICOM phantom—Wilms' tumor example 
To illustrate that our phantom can be used for dose calculations within a commercial TPS, 
we designed a treatment plan in RayStation and calculated dose to two organs at risk for our 
DICOM format phantom. The treatment plan was designed to be representative of a typical 
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RT plan for an individual in the Childhood Cancer Survivor Study (CCSS) cohort. To do this, we 
selected a common type of paediatric cancer, Wilms' tumor. We then performed a query of 
7451 individuals in the CCSS expanded cohort (Leisenring et al 2009, Robison et al 2009) who 
received RT between 1985 and 1999 (data collected under IRB approved protocol and RT 
records previously abstracted). We identified 318 individuals diagnosed with Wilms' tumor 
who were treated with anterior-to-posterior and posterior-to-anterior (AP/PA) directed 
abdominal flank fields. From these 318 treatments, we selected the median treatment field 
parameters to simulate a typical (6 MV) right-sided flank field RT plan: [1] age at RT: 3.9 years 
(range 0.45–20.9 years), target dose 10.80 Gy (range 1.08–36.72 Gy), [3] superior field 
border: diaphragm (N = 203), [4] Inferior border: L5 (N = 139). The right-sided AP/PA 
treatment fields are illustrated for a 3.9-year-old phantom in FORTRAN and DICOM formats in 
Figure 4. Doses to two organs at risk—the liver and pancreas—were calculated. Specifically, 
we calculated the mean dose received by each organ and the percentage of each organ that 
received dose ≥ 5 Gy (V5). For comparison, we simulated the same treatment for our 






Figure 4: Right-sided AP/PA treatment fields simulated for Wilms' tumor RT plan on a 
phantom scaled to 3.9 years in (a) FORTRAN and (b) DICOM formats. The coordinates of the 
field isocenters and field borders were the same in both planning systems. 
3. Results  
3.1 Phantom modeled in DICOM standard 
The age-scalable computational phantom modeled in DICOM format is illustrated in 
Figure 5, which includes 3D renderings of our phantom generated in RayStation TPS and 









Figure 5: Illustration of TPS generated 3D renderings of age-scaled phantoms modeled in 
DICOM. Selected organs (brain, lungs, heart, liver, and stomach) were also rendered for each 
scaled phantom. 
 
3.2 Comparison between phantom modeled in FORTRAN and DICOM 
A histogram illustrating distribution and range of error in reproducing correct locations of 
body-region corner points is shown in Figure 6. All observed differences were within 3%, with 
0% being most frequently observed. The results of the percent difference calculations in the 
volumes of the head, neck, and trunk of the two phantoms are shown in Table 1. For the 




Figure 6: Histogram showing the frequency of percent differences in the corner points of 
body regions (excluding legs and arms) of the DICOM phantoms.  









1 2 3 5 8 10 15 18 
Head 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Neck 1.9 0.1 0.0 0.3 0.3 0.1 0.4 0.0 0.2 0.2 
Trunk 2.8 1.2 1.3 1.2 1.3 1.3 1.3 1.3 1.2 1.2 
The normalized mean square distance calculations resulted in strong agreement in the 
location of organs across the studied age range. The maximum NMSD was 7.80 ×
10−2 mm for occipital lobe of age 1 month. When we compared the percent differences in 
the phantoms' heights modeled in DICOM and FORTRAN, we found accurate agreement 
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(difference = 0%) between the phantoms for ages 1, 3, 5, 10, and 15 years and a difference of 
0.03% between the phantoms for age 18 years. 
3.3 Comparison of DICOM phantom with population height data 
Figure 7 shows, for ages 1 month through 20 years, a comparison of the heights of the 
age-scaled DICOM phantoms with the averages of the 50th-percentile CDC reported heights 
for males and females. The differences were 3.6, 2.1, 0.3, 1.4, 0.6, 1.0, and 0.7% for ages 2, 3, 
5, 8, 10, 15, and 18 years, respectively. For 1 month, 6 months, and 1 year, the differences 
between the DICOM phantom heights and the WHO 50th-percentile heights were 6.9, 3.1, 
and 2.6%, respectively. 
 
Figure 7: Comparison of the heights of the computational phantom modeled in DICOM with 
the WHO/CDC heights(Centers for Disease Control and Prevention 2000). 
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3.4 Comparison of organ masses of DICOM phantom with ICRP 89, and UF/NCI reference 
hybrid phantom data 
The masses of nine organs from our DICOM phantom are listed in Table 2. Also reported 
in Table 2, are the absolute differences between organ masses in our phantom and those 
reported for ICRP 89 and UF/NCI phantoms. The differences are all negative (apart from 
newborn brain), i.e., the organ masses in both reference datasets are substantially greater 









Table 2: Mass (in gram) of DICOM phantom organs and comparison with masses from ICRP 89 and UF/NCI reference hybrid voxel phantom data.  In 
each case, the difference between DICOM phantom organ mass and ICRP 89 or UF/NCI reference masses were calculated 
 






























- UF ref. 
Heart 12.27 -33.73 -13.68 24.62 -73.38 -73.45 42.39 -177.61 -176.98 76.62 -293.38 -292.54 135.68 -464.32 -462.82 173.26 -556.74 -555.45 
Brain 449.40 69.40 128.27 651.56 -298.44 -298.25 900.89 -344.11 -343.83 1003.63 -306.37 -305.84 1083.11 -276.89 -274.11 1153.46 -221.54 -215.17 
Liver 54.32 -75.68 -75.36 108.86 -221.14 -220.61 181.62 -388.38 -383.20 318.69 -511.31 -510.14 572.21 -727.79 -726.37 738.61 -861.39 -858.70 
Lungs 41.43 -18.57 -18.30 84.32 -65.68 -65.44 146.05 -153.95 -152.58 259.93 -240.07 -238.22 460.98 -364.02 -361.87 590.71 -484.29 -481.42 
Stomach 25.27 -21.73 -7.05 48.26 -38.74 -38.41 75.79 -57.21 -56.59 133.35 -68.65 -67.44 225.17 -94.83 -94.01 287.68 -97.32 -97.14 
Pancreas  3.13 -2.87 -2.86 5.03 -14.97 -14.90 7.28 -27.72 -27.67 11.56 -48.44 -48.37 20.56 -84.44 -84.19 26.31 -103.69 -103.26 
Kidneys  2.76 -22.24 -23.48 5.05 -64.95 -68.31 9.21 -100.79 -105.85 16.22 -163.78 -172.78 27.62 -217.38 -229.23 34.17 -258.33 -272.23 
Thyroid 0.26 -1.04 -1.03 0.44 -1.36 -1.35 0.60 -2.80 -2.80 0.55 -7.35 -7.35 0.61 -11.39 -11.31 0.62 -17.88 -17.82 
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3.5 Results from dose calculation (Wilms’ tumor example) 
The V5 and mean dose (Gy) for liver and pancreas calculated with our in-house calculation 
system (with FORTRAN phantom) and the RayStation TPS (with DICOM phantom) are 
reported in Table 3; percent difference in each case is also reported. The percent differences 
between mean doses for liver and pancreas were −4% and 1%, respectively. The percent 
differences between V5 values for liver and pancreas were −6%and 7%, respectively. 




V5  (%) Mean Dose (Gy) 
DICOM FORTRAN % Diff. DICOM FORTRAN % Diff. 
Liver 91% 96% -6% 9.55 9.99 -4% 
Pancreas 72% 67% 7% 7.57 7.50 1% 
 
4. Discussion 
In this study, we successfully adapted our phantom model from FORTRAN to DICOM, 
allowing for importation into any commercial TPS (RayStation, Eclipse, Pinnacle, Monaco, 
etc), where it can be used for a variety of dosimetry studies. Analogous to our FORTRAN 
phantom, our DICOM phantom can be scaled to any age and can be used to perform 
retrospective dose reconstructions for survivors treated with contemporary RT. In such 
studies doses to distant organs will need to be retrospectively reconstructed on 
computational phantoms because CT images used for treatment planning may not be 
available for epidemiologic studies, and even if they are, the CT data will be limited to 
anatomy near the target volume and will not include distant structures that are typically of 
interest in such epidemiologic studies. For example, for female pediatric brain cancer 
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survivors, whose CT scans only included the head and possibly the neck regions, organs of 
interest for late effects studies may include the heart, breasts, and ovaries, for which 
anatomical information is not present in the CT scan. In such cases, our phantom can be 
scaled to any age at RT and co-registered with the patient CT scan, and then doses to other 
organs can be reconstructed using the methodologies described in previous studies (Stovall 
et al 2006, Howell et al 2019). An important reason for using our phantom in late effect 
studies for cohorts treated with contemporary RT is to facilitate comparison with cohorts 
treated with historic RT. The dosimetry for RT-related late effects studies in the literature has 
been predominantly conducted using the MD Anderson Late Effects Group phantom. Howell 
et al (2019) reports more than one hundred late effects studies for which the MD Anderson 
Late Effects Group performed dose reconstructions for cohorts with thousands of childhood 
cancer survivor studies, e.g. the CCSS, St. Jude Lifetime (Hudson et al 2011, 2017), Adult Life 
after Childhood Cancer in Scandinavia (Asdahl et al 2015), and Dutch Childhood Oncology 
Group (Teepen et al 2017). Furthermore, other reference phantoms, e.g., UF/NCI, while 
anatomically more realistic compared to our phantom, are only available for discrete integer 
ages and cannot be scaled to any arbitrary age. 
Our validation studies showed that our phantom was correctly adapted from FORTRAN to 
DICOM. The histogram analysis of the percent differences between the corner points of head, 
neck, and trunk body regions and volumes of the body regions were in good agreement 
(within 3%) and the majority (94.4%) of corner points agreed within 1%. The DICOM model of 
the phantom consists of organ contours developed from a grid of points that were obtained 
after transforming the points of the FORTRAN model of the phantom. The points defining the 
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organs were conserved quantitatively between the FORTRAN and DICOM models, with mean 
differences being less than 0.1 mm for all organ points. The maximum NMSD obtained was 
7.80 × 10−2𝑚𝑚 for occipital lobe of age 1 month. The heights of our age-scaled phantom 
agreed with WHO/CDC data within 7% from infant to adult, with best agreement for ages 5 
years and older (<2%). 
By modelling our phantom in DICOM, and, in particular, by converting our phantom's 
organs from grids of points to contours from which volume (and mass) could be derived, we 
were, for the first time, able to compare our phantom's organs masses with those from other 
reference phantoms. The results of this analysis demonstrated that the organ masses of our 
DICOM phantom are much less than those in both reference phantoms. The differences were 
similar in magnitude for comparisons with ICRP 89 and UF/NCI reference phantoms because 
the UF/NCI phantoms were adjusted to match ICRP 89 data (Lee et al 2010). It was not 
unexpected that our organ masses would differ from more recently developed ICRP 89 and 
UF/NCI phantoms because the organs in our FORTRAN phantom, which were the basis of the 
organs in the DICOM phantom, were developed from crude sampling of organ points from 
cross-sectional anatomical images (Howell et al 2019). While the differences in mass were 
large, it is important to underscore that dosimetry conducted with our in-house dose 
calculation methodology and FORTRAN phantom did not use organ masses for calculations. In 
that system, we calculated doses to the individual points comprising an organ. Then from 
those data, the mean organ doses were taken as the mathematical average of the point 
doses. Similarly, dose-volume metrics were approximated from percentage of points, e.g., 
the V5 was estimated from the percentage of points with dose ≥5 Gy. 
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In this study, we also illustrated that our phantom can be used for dose calculations 
within a commercial TPS. This example calculation demonstrated that our DICOM phantom 
can be scaled to any age (here 3.9 years), not just the ages illustrated in Figure 1. Also, by 
selecting an example case that was typical of the types of calculations for which our in-house 
calculation method has been used, we were able to perform the same calculation for both 
the FORTRAN and DICOM format phantoms for direct comparison. Notably, we observed 
reasonably good agreement (within 7%) between the two calculation methods with the 
FORTRAN and DICOM phantoms (Table 3). We attribute the differences between doses to the 
more accurate collapsed cone dose calculation algorithm in the RayStation TPS compared to 
the very simple 2D method used in our in-house calculation system. 
While the DICOM model of our phantom was validated and can be used for dose 
calculations in a commercial TPS, the comparison of organ masses for our DICOM phantom 
and the organ masses from the reference phantoms revealed that our organs are too small 
and highlighted that refinement is necessary. The enhancement that we accomplished in this 
study, converting our phantom from FORTRAN to DICOM format, opens new avenues to 
achieve this. Namely, we can now register the DICOM model of our phantom with patients' 
and other phantoms' (Lee et al 2010) CT images to evaluate the correspondence of organs. 
Phantoms enhancements that we are working towards include, redefining organs to be 
more anatomically realistic in size and shape and adding substructures to more organs. For 
example, the heart, an important organ for RT-related late cardiac disease, was developed 
using an anatomy atlas and was modeled as a 55 point grid with no substructures. We can 
enhance the shape and size of the heart based on the realistic anatomy and compare the new 
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model with models from UF/NCI reference phantoms. The heart model in our phantom could 
be further refined by adding substructures and increasing the resolution of points that would 
enable calculations of RT doses to specific substructures. These substructure doses could be 
used to further enhance dose-response models for RT-related late cardiac disease, which at 
present are based on whole-heart doses (Mulrooney et al 2009, Haddy et al 2016, Bates et al 
2019). Additionally, other organs in the FORTRAN phantom were designed with low 
resolution, e.g., kidneys and pituitary glands have 15 and 1 points, respectively. For these 
low-resolution organs, we were not able to create contoured volumes that can structurally 
represent the organ in the RayStation TPS. Finally, we are presently working on adding a 
colorectal model to our phantom to understand the relationship between dose to the 
colon/rectum (and its substructures) and treatment-related colorectal second cancers in 
childhood cancer survivors. Existing studies on this topic have not included detailed colorectal 
dosimetry (Henderson et al 2012, Nottage et al 2012, Tukenova et al 2012). 
5. Conclusion 
We successfully adapted our age-scalable computational phantom from the FORTAN 
language to DICOM format, which can be imported into any commercial TPS. The modelling 
of the phantom in DICOM allows visualization of organs and body regions in three 
dimensions, which was not done before. Most importantly, the phantom modeled in DICOM 





Chapter 4: Scaling of Whole-Body Computed Tomography-Based 
Anatomy to Any Age 
This chapter is based on the following manuscript which was submitted to Biomedical Physics 
& Engineering Express Journal, and it is under review. 
A.C. Gupta, C.A. Owens, S. Shrestha, C. Lee, S.A. Smith, R.E. Weathers, T. Netherton, P.A. 
Balter, S.F. Kry, D.S. Followill, K.T. Griffin, J.P. Long, G.T. Armstrong, R.M. Howell, 
“Implementation and Validation of Non-Uniform Body Region Specific 3D Age-Scaling 
Functions to Scale Whole-Body Computed Tomography Anatomy to Any Arbitrary Age for 
Late-Effects Studies of Childhood Cancer Survivors,” In Review (2021).  
This chapter describes the results of Specific Aim 2: Apply ASFs to scale the whole-
body CT based anatomy to any arbitrary ages, and validate scaling with ground-truth 
anatomy and reference data. 
1. Introduction 
In the decades after treatment, childhood cancer survivors are at high risk for developing 
treatment-related late effects due to high survival rates for pediatric cancers (> 84%) and 
long-life expectancy (Travis and Boice 2012, Armstrong et al. 2016, Gibson et al. 2018). 
Radiation epidemiologic studies of childhood cancer survivors seek to establish dose-
response relationships between specific late effects and the dose from radiotherapy (RT) to 
the organ in which the late effect occurred (Travis et al 2011). Most childhood cancer 
survivor cohorts include survivors treated in the pre-computed tomography (CT) era of RT 
and organ doses must, therefore, be estimated by reconstructing RT treatment fields on 
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surrogate anatomy. The most used surrogate anatomy for retrospective RT reconstruction is 
computational phantoms. 
In the last 50 years, computational phantoms have experienced dramatic advancements, 
beginning with the ICRU spherical models (ICRU 1992a) and simple first-generation stylized 
phantoms at discrete ages (ORNL 1966) to the advanced  age-scalable computational 
phantoms (Howell et al 2019) and to the highly realistic patient-dependent hybrid 
computational phantom libraries (Lee et al 2010, Segars et al 2010, Zaidi and Tsui 2009, Xu 
2014).  Taking advantage of the modeling flexibility, the reference size hybrid phantoms were 
modified into body size-dependent phantoms such as the phantom library developed by the 
University of Florida and National Cancer Institute (UF/NCI) consisting of 158 pediatric 
phantoms of various heights and weights (Geyer et al 2014). When using such phantom 
library to retrospectively reconstruct RT treatment of a childhood cancer survivor with no CT 
images, a phantom of nearest height and/or weight of the survivor can be selected as a 
surrogate. This approach is only feasible when both the height and weight of a survivor are 
known (Kalapurakal et al 2018), which, however, is not always the case in historic RT records. 
Therefore, the age at RT is commonly used as a surrogate for height and weight where 
reference size phantoms are adopted. Since the reference size phantoms are usually available 
at discrete ages (e.g. newborn, 1, 5, 10, 15, and adult), the nearest available discrete age 
would be selected for RT reconstruction for a survivor. For example, the 5-year-old reference 
size phantom would be selected for a survivor that was 3.9-year-old at the time of RT 
treatment. This age discrepancy, further increases uncertainty in dose reconstruction as the 
organ size of a 3.9-year-old survivor would be smaller than that of a standard 5-year-old 
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phantom which, (1) for partially in-beam organs, would result in a larger fraction of the 
organs being in-beam, overestimating dose and (2) for out-of-beam organs, would result in 
organs being farther from the field, underestimating organ dose. Dosimetric uncertainties 
can translate to uncertainties in risk estimation, which in some instances can be as much as 
70% (Vũ Bezin et al 2017).  
Since age is generally the only height and weight surrogate available in historic RT 
records, age-based scaling of computational phantoms is frequently used in RT epidemiology 
studies. The MD Anderson Late Effects Group developed and validated a computational 
phantom (used in over 120 radiation epidemiology studies) that can be scaled to any ages 
from infant to adult (Stovall et al 2006, Howell et al 2019) based on age-scaling functions 
(ASF) that were developed from growth data of 4,127 U.S. infants, children, and youths 
through 18 years of age (Snyder et al 1977). This capability is compatible with what is 
typically available in historic RT records and also allows for the scaling of the computational 
phantom to the exact age of the survivor at the time of RT treatment. Recently, the MD 
Anderson phantom and the ASFs were implemented and validated in the Digital Imaging and 
Communication in Medicine (DICOM) standard (Gupta et al 2020). This adaptation makes it 
possible to use ASFs to scale other DICOM-formatted phantoms. The main purposes of this 
investigation were to (1) conduct a feasibility study to scale reference size discrete age 
phantoms from the UF/NCI phantom library to both discrete and continuous valued ages that 
are common in RT epidemiologic studies of childhood cancer survivors and (2) to evaluate the 
dosimetric impact of using exact age-scaled phantoms as opposed to nearest-age matched 
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phantoms.  Hereafter, we have interchangeably used discrete aged phantoms to represent 
reference size UF/NCI phantoms. 
 
2. Methods 
2.1 The University of Florida/National Cancer Institute (UF/NCI) computational phantom 
library 
We adopted the UF/NCI computational phantoms to test our age-scaling methods.  The 
phantom library consists of two groups: the reference size phantoms and the body size-
dependent phantoms. The reference size phantom library was developed from the manual 
segmentations of high-resolution CT scans of cadavers and patients at different discrete ages 
from 6 days to 25 years (Lee et al 2010). The phantoms were originally scaled to match the 
50th percentile heights, arm lengths, acromial breadth, and body region circumference from 
several reference datasets as reported in Lee et al (2010) and Johnson et al (2009). The organ 
volumes were represented by a single volume which precluded its comparison with the 
International Commission on Radiological Protection Publication (ICRP) 89 data as autopsy 
data are mostly reported in terms of wall and internal contents of the organs. Therefore, the 
single organ volumes were later separated into organ wall, tissue, blood, and air for discrete 
aged phantoms. Furthermore, skeleton, muscles, lymph nodes, and blood vessels were added 
to make the phantom more anatomically realistic. With the incorporation of updated organs 
and additional structures at discrete ages, the ICRP adopted the UF/NCI pediatric male and 
female phantoms (age: 6 days, 1, 5, 10, and 15 years) in ICRP 143 report (Bolch et al 2020). 
Later, the heights of the phantoms were up-/down-scaled and the circumference of the body 
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regions was modified (by adding fat layer) to create a library of 158  pediatric and 193 adult 
phantoms of varying heights and weights i.e. body-mass index (BMI) (Geyer et al 2014). These 
phantoms were later converted to DICOM-RT format, with accompanying CT images and 
segmented organ structures, using the DICOM-RT Generator developed in Griffin et al (2019). 
For our feasibility study, we used reference size male and female UF/NCI phantoms at 
ages 1, 5, 10, 15, and 35 years as this phantom set allows us to validate our age scaling 
methodologies at discrete ages and also allows us to scale the phantoms to any continuous-
valued ages that are common in RT epidemiological studies of pediatric survivors. We 
excluded the newborn phantoms because the neck is flexed in these phantoms, which results 
in an inherent error due to the difference in neck orientation; we are only interested in 
scaling errors from our ASFs.  
For our dosimetric assessment, we obtained one reference size 5-year-old UF/NCI 
phantom and seventeen body-size dependent phantoms that were created from the 
reference 5-year-old phantoms. We selected the age of 5 years in our study because this is 
the closest age to the median age of Childhood Cancer Survivor Study (CCSS) cohort 
(Leisenring et al 2009, Robison et al 2009) which is adopted in this study  to obtain 
continuous valued-ages that are common in RT epidemiologic studies (as described in detail 
in section 2.4). The age, number, height, and weight of the phantoms used in this study are 





Table 4: Parameters of UF/NCI phantoms selected in this study 
Age (years)  
Number of 
phantoms  
Heights (cm)* Weight (kg)  Type 
 M F M F M F  
Phantoms used in the feasibility study 
1 1 1 76.4 76.4 10 10 Reference 
5 1 1 110.3 110.3 19 19 Reference 
10 1 1 139.9 139.9 32 32 Reference 
15 1 1 169.9 161.9 56 53 Reference 
Adult (35) 1 1 174.8 163.6 73 60 Reference 
Phantoms used in dosimetric assessment studies 
5 9 8 
95.3-
115.5 
95.3-115.5 15-30 15-30 
Body-size 
dependent 
*Heights were measured from DICOM file. M= male and F=female 
 
2.2 Modification of MD Anderson Late Effects Group scaling methodologies for UF/NCI 
phantoms  
2.2.1 Original MD Anderson Late Effects Group scaling methodologies 
Our baseline 3D phantom (hereafter called the generic phantom) consists of body 
regions that define the head, neck, trunk, legs, and arms, and 25 organs (Stovall et al 2006, 
Howell et al 2019). Phantom scaling methods are described in detail in Gupta et al (2020) and 
will be summarized here. The generic phantom is scaled by body region and direction-specific 
ASFs, which account for non-uniform growth of the generic phantom to any arbitrary age in 
right-left (RL) or x, anterior-posterior (AP) or y, and inferior-superior (IS) or z directions. Since 
the ASFs are body region-specific, the organs located within each body region are scaled with 
the same ASFs as the body region. The ASFs have two components and hence, scaling is 
executed in two - steps. In the first step, the body region and direction-specific scaling factors 
are determined based on the target age. For the ages a ϵ { 0.1, 1, 3, 5, 10, 15, 18 years}, we 
use discrete scaling functions, Fdis, which was originally estimated from 50
th percentile body 
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measurements reported by Snyder et al (1977). For any other ages, we perform linear 
interpolation in between closest discrete ages to estimate the continuous valued age scaling 
function, Fcont. In the second step, Fdis or Fcont are incorporated in the body region and 
direction-specific transformation equations which transform the 3D points with respect to 
the reference lines and boundaries of body regions. For example, in the RL directions, points 
were transformed about x=0, and in the AP direction, points were transformed with respect 
to the anterior boundary of the body regions. This enables accurate scaling and localization of 
the 3D points of each body region and organ. Lastly, since the body regions and organs are in 
point format, the points for each structure are converted to surface contours using convex 
hull algorithms.  
2.2.2 Modifications in scaling factor estimation 
Since the UF/NCI phantoms are available at discrete ages, we developed a protocol to 
apply our ASFs to scale the UF/NCI phantoms from discrete ages to our generic phantom 
dimensions and then scale from the generic phantom dimensions to any arbitrary age. 
Therefore, the scaling function, Fa→at , in a head-first-supine orientation, is obtained by taking 
the ratio of scaling functions Fdis or Fcont of a specified body region, r, in a direction, d, at an 
arbitrary target age, at, and Fdis of the same r in the same direction but at the original 
discrete age, a, as shown in equation (9). 
Fa→at(d, r, a) =








d ϵ {left to right (x), anterior to posterior (y), and inferior to superior (z)} 
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r  ϵ {head (h), neck (n), trunk (tr), arms (ar), legs (lg)} 
a  ϵ {0.1 (1 month), 1, 3, 5, 10, 15, 18}, and  
at  lies in the age intervals {[0, 1), [1, 3), [3, 5), [5, 10), [10, 15) and [15, 18)} 
Fx, Fy and Fz are the scaling factors and are represented in the matrix form. 
 
2.2.3 Modification in transformation equations 
Two factors drive the modification of our original transformation equation: the 
availability of the UF/NCI phantom in DICOM format and adoption of the RayStation 
treatment planning system (TPS), which is currently used in our clinic. The body regions and 
organs of the UF/NCI phantom are in 3D region of interest (ROI) format in RayStation and the 
TPS has the “TransformROI3D” function where scaling, rotation, and translation factors are 
entered in the 4x4 transformation matrix 𝐓 as shown in equation (10). Since the 
transformation that is performed in RayStation only involves scaling and translation, all the 
rotational components are equal to zero. 
𝐓 =  [
Fx 0 0 tx
0 Fy 0 ty
0 0 Fz tz
0 0 0 1
] 
10 
Where, Fx, Fy, and Fz are the scaling factors (from equation (1)) that scale an ROI in the 
RL, AP, and IS directions, respectively. tx, ty and tz translate an ROI in the RL, AP, and IS 
directions, respectively.  
To adapt our original transformation equations (Gupta et al 2020) correctly in the 
“TransformROI3D” function, we modified our original approach which we will summarize 
here. We first performed scaling of ROIs using scaling matrix 𝐓𝐬 (equation (11)) where 
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rotational and translational elements are zero. We then translated the scaled ROI using 𝐓𝐭 
(equation (12)) where scaling and rotational elements are zero. Equations (11) and (12) are 
the derivatives of equation (10). 
𝐓𝐬 =  [
Fx 0 0 0
0 Fy 0 0
0 0 Fz 0
0 0 0 1
] 
11 
𝐓𝐭 =  [
1 0 0 tx
0 1 0 ty
0 0 1 tz




If R(x,y,z) is the unscaled 3D ROI that spans the patient in the RL, AP, and IS directions, then 
the scaled ROI RT(x, y, z) at an arbitrary age at is obtained by  
RT(x, y, z) =  𝐓𝐬 ⋅ R(x, y, z) 13 
The above operation results in displacements in the centroids of the body regions and organs 
as each body region and its corresponding organs undergo non-uniform scaling. To remedy 
this, we first correct the centroids of the body region and then the centroids of the organs 
(also presented in Figure 8). For body regions, we first determine the centroid of the scaled 
head ROI. Then, we translate it back to centroid before scaling. We then translate all other 
scaled body regions to the mid-plane (in AP and RL directions) of the scaled head ROI using 
𝐓𝐭. The translations in IS direction, for correct body region stacking, is determined by scaling 
the distance between the centroids of unscaled head and body regions ROI  as described in 
more detail in Gupta et al (2020).  Organs ROI are translated with respect to centroids and 
the anterior and upper boundary of the body region they belong to. This results in the 
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accurate scaling of the original depth of organs in all directions. Therefore, the centroids 
(Xct(o), Yct(o), Zct(o)) of the scaled organ ROI, o, are given by: 
Xct(o) = Xct(r) ± abs[Xc(o) − Xc(r)] ⋅ Fa→at(x, r, a) 14 
Yct(o) = Yabrt(r) + abs[Yc(o) − Yabr(r)] ⋅ Fa→at(y, r, a) 15 
Zct(o) = Zubrt(r) − abs[Zc(o) − Zubr(r)] ⋅ Fa→at(z, r, a) 16 
Where,  
Xct(r) and Xc(r) are the centroids of the scaled and unscaled body region, r, in the RL 
direction, respectively. The + and – signs accounts for the organs located in the right 
and left directions, respectively, from the mid-plane of the patient 
Xc(o), Yc(o) and Zc(o) are the centroids of unscaled organ, o, in the RL, AP, and IS 
directions 
Zubrt(r) and Zubr(r) are the upper boundaries of scaled and unscaled body regions, r, 
in the IS direction.  
Once (Xct(o), Yct(o), Zct(o)) is calculated, the organ ROIs are translated to their correct 
centroid using 𝐓𝐭. 
Although UF/NCI phantoms were used in this study, the above methodologies can be applied 
to any DICOM-compatible phantom or whole-body patient anatomy for which ROI of the 
body regions and organs of interest are available.  
2.3 Scaling of computational phantoms to arbitrary ages 
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To perform the scaling and generating of DICOM files of the scaled phantoms, DICOM 
files of the original phantoms are imported into the RayStation v10B TPS. We developed 
Python scripts that can scale any whole-body CT-based anatomy from one age to another as 
long as we have organ contours/ROI or points representing the ROI. This task is accomplished 
with three different in-house Python scripts using the following steps. A general overview of 
the steps for downscaling a 5-year-old to a 3.9-year-old is presented in  Figure Error! 
Reference source not found.8. 
1. Data preparation: The current and target ages of the phantom or patient anatomy 
are entered in the Python script. A quality check is performed to ensure that the 
phantom is in head-first-supine orientation and the names of all organs within the 
phantom match a name from the list of names that are defined in the script.  
2. Body region separation: Since the UF/NCI phantom does not have the body regions 
defined, we divided the whole-body ROI into head, neck, trunk, arms, and legs based 
on standard bony landmark measurements performed on the phantom. For example, 
the boundary of the head and neck is at the intersection of the 2nd and 3rd cervical 
vertebrae. The separation was performed using ROI algebra in the RayStation TPS.  
3. Localization of organ centroids: Distances between the organ centroids and the 
boundary of body regions are calculated. In the RL, AP and IS directions, the distance 
is calculated with respect to the midline of the patient, the frontal boundary of the 
cuboid enclosing the body regions, and the upper boundary of the cuboid enclosing 
the body regions. The calculated distances are scaled using equation (9). 
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4. Scaling and translation of body regions and organs: Using equations (9) and (13), 
each body region is scaled and translated per the description in section 2.2.3. The 
organs are also scaled using equations (9) and (13) and are translated using equations 
(14)-(16) 
5. Post-processing: The boundaries of body regions in the IS direction are checked for 
gaps or any unanticipated translation. The manual translation is performed for such 
cases. Steps 2 through 4 involve multiple ROI algebra operations, which could result in 
small holes in the contours, contour overlaps, and fragments. This is fixed by using the 
“Simplify contours” function in RayStation.  
6. Assignment of Hounsfield unit (HU) values: Once the phantoms are scaled in the TPS, 
the size of the body regions/organs changes in each slice, and as a result, the 
contour/ROI boundaries do not cover the same voxels of the CT scan. Because of this, 
the HU values originally assigned to each voxel no longer represent the scaled 
anatomy. To assign the correct HU values to each voxel, the DICOM files are exported 
and are processed with our Python script. The following lists the sub-steps within step 
6.   
a. Using the polygon function of the skimage.draw Python module (Van Der Walt et 
al 2014), we trace the boundary of contours on the slices of CT scan. Using the 
traced boundary, we create masks on each slice and then we record the voxel 
locations. 
b. For discrete ages, we obtain HU values from the DICOM RT generator software 
(Griffin et al 2019). For continuous-valued age, we perform linear interpolation to 
estimate the HU values. 
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c. For each scaled organ ROI, we assign same HU values to each voxel that reside 
within the ROI boundary. 
The result of step 6 is a CT scan with voxels that are assigned HU values based on the 
ROI boundary that a voxel resides in.  
7. Quality Check: DICOM files are imported into RayStation TPS and are visually 
inspected by the user for artifacts and discontinuity of the voxel HU values at ROI 
boundaries. Contours are simplified and holes are removed. Afterward, the DICOM 




Figure 8: Steps used in the scaling process of the UF/NCI phantoms to arbitrary ages.  Scaling 
of a reference size 5-year-old to 3.9-year-old is shown as an example. 
2.4 Feasibility and validation study 
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For the feasibility study using our ASFs, we downscaled both male and female  discrete-
aged phantoms (5, 10, 15 and 35 years) to the nearest lower discrete ages (1, 5, 10 and 15 
years), resulting in 8 scaled phantoms (4 male and 4 female), and validated the scaled 
phantoms with the original UF/NCI phantoms available at that age, i.e., ground-truth 
phantoms. For example, the 5-year-old male phantom was scaled to the size of a 1-year-old 
phantom and was validated with a ground-truth 1-year-old male phantom. To show the 
feasibility of scaling discrete-aged phantoms to continuous valued-aged phantoms, we 
downscaled the nearest age-matched discrete-aged phantoms to three different ages, 
representative of the CCSS expanded cohort. Specifically, both male and female 5-year-old 
phantoms were downscaled from reference size UF/NCI phantom library to 3.9-year-old 
phantoms (median age at RT for Wilms’ tumor patients in CCSS expanded cohort). Similarly, 
both male and female 10-year-old phantoms were downscaled to 8.1 and 9.0-year-old 
phantoms (median ages at RT for craniospinal tumor patients and for entire CCSS expanded 
cohort, respectively). A total of 14 phantoms were downscaled using two methods; 8 
phantoms scaled to nearest lower discrete age and 6 phantoms scaled to median ages based 
on CCSS participants’ ages at RT. 
We used two approaches to validate the scaling of phantoms. In the first approach, we 
compared the overlap and organ displacement parameters between the scaled and ground-
truth UF/NCI phantoms at discrete ages. In the second approach, we compared the 
anthropometric parameters of scaled phantoms with ground-truth phantoms, and with 
reference data from ICRP 89 (ICRP 2002) and the Center for Disease Control and Prevention 




2.4.1 Quantitative assessment of body region/organ overlap and displacements at discrete 
ages 
The main goal of quantifying the overlap and the displacement was to determine the 
body-regions/organs that are most and least affected by scaling, in terms of their size and 
position. To quantify the overlap between two ROIs of a body region/organ, we first 
performed rigid registration between the scaled and ground-truth phantoms at discrete ages 
using the centroid of the trunk body region. Using built-in functions within RayStation v10B, 
we calculated the Dice similarity coefficients (DSC) and mean distance to agreement (MDA) 
for the whole-body, brain, heart, liver, pancreas, and kidneys between the scaled and 
ground-truth phantoms. The DSC is a measure which calculates the overlap between two 
ROIs. The values of DSC ranges from 0 to 1 with 0 indicating no overlap and 1 indicating 
complete overlap (Dice 1945). A DSC value of 0.7-0.8 is considered good agreement (Dice 
1945, Mattiucci et al 2013, Thomson et al 2014). The MDA estimates the average similarity 
between the two ROIs by estimating the average of  distance between the point per voxel on 
the surface of two ROIs (Brock et al 2017). A value of MDA=0cm represents that the 
boundaries of two ROI is perfectly overlapped. 
To estimate the displacements in the body regions/organs, we calculated the Euclidean 
distance (ED) between the centroids of the body regions/organs of scaled and ground-truth 
reference size UF/NCI phantoms using the equation below- 
𝐸𝐷 = √(𝑥𝑐𝑡 − 𝑥𝑐)
2
+ (𝑦𝑐𝑡 − 𝑦𝑐)
2






where, (xc, yc, zc) and  (xct , yct , zct) are the centroids of body regions/organs ROIs in 
ground-truth and transformed (scaled) phantom, respectively.  
2.4.2 Quantitative assessment of anthropometric parameters at all ages 
The goal of assessing the anthropometric parameters was to gauge the standing 
heights and organ masses of the scaled phantom with respect to reference data. First, we 
compared the standing heights of the scaled phantoms with those of the ground-truth 
phantoms at discrete ages and reference data from CDC at all ages. Specifically, we calculated 
the percent difference (equation (18)) between the standing heights of scaled phantoms, and 
(1) heights of the ground-truth phantoms, and (2) CDC-reported 50th percentile heights for all 






Where, Sh is the height of a scaled phantom and Gh is the height from a ground-truth 
phantom or CDC data.  
Second, we compared the scaled organ masses with ICRP 89 reference data. First, we 
estimated the mass of the scaled organs by taking the product of the organ volumes from 
RayStation and ICRU 46 reported reference densities (ICRU 1992b). We then calculated the 
difference between the masses of scaled organs and ICRP 89 reported organ masses. The 
calculation was performed for brain, heart, lungs, liver, stomach, and kidneys and all of the 
male and female discrete-aged phantoms, as ICRP 89 data are unavailable for 3.9-, 8.0-, and 




2.5 Difference in organ dose due to scaling- Wilms’ Tumor RT plan example 
In historic RT cohorts, dose reconstructions are based on treatment parameters 
abstracted from the RT records, including field size and field location (based on anatomical 
landmarks). In such studies, patients’ heights and weights or CT images are not always 
available. Thus, if one were to do the dose reconstructions for survivors at continuous-valued 
ages, the nearest age-matched phantom would be selected, and the coded field would be 
reconstructed on that phantom. In this scenario, a patient’s coded field size would not be 
adjusted in size for the differences in age between the patient and the closest age-matched 
phantom.  However, in contemporary treatments, RT records include patients’ height and 
weight and CT images at the time of RT. In this scenario, with the anatomical information, the 
field sizes could be appropriately adjusted to better align with the anatomical landmarks 
from the RT records. Therefore, in our dosimetric assessment, we considered both scenarios 
and performed a dosimetric assessment between the exact age-scaled and nearest age-
matched discrete-aged phantoms by designing typical RT plans in RayStation TPS for Wilms’ 
tumor as this is one of the common pediatric cancers in the CCSS.  
In the first study, we downscaled a reference size 5-year-old phantom to a 3.9-year-old 
and constructed right flank fields identical in size on both the 3.9-year-old and 5-year-old 
phantoms. Specifically, 6 MV AP/PA right flank fields were simulated on a 3.9-year-old with 
the superior field border at 2 cm below the liver/heart boundary, the inferior border at the 
5th lumbar vertebrae, the right border at a 1 cm margin enclosing the liver, and the left 
border enclosing the vertebral bodies. A total of 20Gy was administered to the isocenter 
placed at midplane in AP/PA direction. We then measured the size of the simulated field and 
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reconstructed an identical pair of AP/PA flank fields on a 5-year-old phantom. The volume 
receiving ≥ 15Gy (V15), and the mean dose to pancreas, liver, and stomach were calculated. 
Absolute difference and percent difference were calculated for both phantoms’ RT plans.  
In the second study, we scaled a cohort of seventeen body size-dependent UF/NCI 
phantoms (9 male and 8 female) of created from the 5-year-old reference phantom to 3.9-
year-old and simulated the same standard Wilms’ tumor 3D conformal RT plan on all 34 
phantoms. All of the treatment parameters were the same as the 3.9-year-old of the first 
study except the field size, which varied to maintain identical field borders. Specifically, the 
superior and inferior field borders were set at 2 cm below the liver/heart boundary and the 
level of the 5th lumbar vertebrae, respectively. The medial field border was set enclosing the 
thoracic vertebrae.  Dose to organs that were either fully or partially in-beam was calculated. 
Here, we compared the percent of volume receiving ≥ 15 Gy (V15), mean dose, and minimum 
dose received by 1% (D1) and 95% (D95) between the 5-year-old phantoms and the 
corresponding 3.9-year-old phantoms. Organs included the pancreas, liver, stomach, left 
kidney (contralateral), right kidney, right and left colons, gallbladder, thoracic vertebrae, and 
lumbar vertebrae. To determine if the dose and dose-volume metrics were significantly 
different between treatment plans for the different phantoms, we performed a non-
parametric Wilcoxon rank sum test using the SciPy package of the Python programming 
language. Medians, standard deviations, and p-values (p<0.05 is significant) are reported for 
each metric.  
3. Results 
3.1 Feasibility of scaling UF/NCI phantoms to continuous-valued ages 
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The feasibility of downscaling the reference size UF/NCI phantoms to any arbitrary age 
using our ASF and transformation function is demonstrated in Figure 9. The figure shows the 
downscaled phantoms in standing positions next to their nearest age-matched discrete-aged 
phantom. An important finding of the scaling is that the structural integrity of the phantoms 
is maintained after the scaling, i.e., all of the organs and body regions remained intact with 
no unexpected organ displacement or gaps between body regions 
 
Figure 9: Downscaling of UF/NCI nearest age-matched discrete-aged pediatric male 
phantoms (5-year-old and 10-year-old phantoms) to median ages (3.9 years for Wilms’ 
tumor, 8 years for all cranial tumors, and 9.1 years for all individuals from the CCSS expanded 
cohort) of different CCSS cohorts. 
3.2 Quantitative assessment of overlaps and displacements due to scaling at discrete ages  
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The DSC, MDA, and ED between the scaled and ground-truth reference size phantoms at 
discrete ages for the whole-body ROI and organ ROIs are presented in Figure 10. The whole-
body and brain showed good ROI overlap with median (range) DSCs of 0.91 (0.86-0.92) and 
0.86 (0.58-0.91), respectively. The heart and liver showed average agreement after scaling 
with median DSC of 0.70 (0.61-0.78) and 0.74 (0.38-0.80), respectively. The kidneys and 
pancreas had the poorest overlap agreement with low DSC values of 0.58 (0.45-0.74) and 
0.32 (0.01-0.62), respectively.  
Additionally, the liver, pancreas, and heart showed larger MDA values (i.e. ROI shape 
variations) compared to the other organs. Specifically, the median (range) MDA for liver, 
pancreas, and heart were 0.73cm (0.43-1.79cm), 0.78cm (0.47-2.29cm), and 0.68cm (0.47-
1.1cm), respectively, while the median MDAs for the whole body, brain, and kidneys were 
0.65cm (0.47-0.93cm), 0.51cm (0.34-1.7cm) and 0.62cm (0.29-0.98cm), respectively. 
However, those difference are not very meaningful as the box plot overlaps mostly.  
The brain showed the smallest range of ED displacements with a median ED of 0.97cm 
(0.58-3.67), while the pancreas, whole-body, heart, kidneys and liver showed median EDs to 
2.03cm (0.72-3.82), 1.35cm (1.04-2.3cm), 1.33cm (0.39-1.9cm), 1.04cm (0.41-2.79cm), and 
0.97cm (0.58-4.09cm),  in case of whole-body, heart, liver, pancreas and kidneys, 
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respectively. The liver showed the highest ED displacement (4.09cm) among all organs. 
 
Figure 10: [a] Dice similarity coefficients (DSC), [b] mean distance to agreement (MDA), [c] 
Euclidean distance (ED) between the scaled and ground-truth phantoms at discrete ages for 
whole-body and five different organs are shown. Means are represented by white square 
boxes. 
3.3 Comparison of anthropometric parameters  
The overall trends in standing heights and the percent difference/absolute difference 
between the standing heights of the scaled phantom and reference data (UF/NCI and CDC) 
are shown in Figure 11 and Table 5 at all studied ages. In Table 5, the data are segregated 
into discrete and continuous-valued ages. Overall, the heights of the scaled phantoms were 
within 6.3% (6.9cm) of the ground-truth phantom and CDC 50th percentile height data. Better 
agreement (within 3% or 3.9cm) was observed in the case of the discrete-aged phantom as 
compared to the phantoms of continuous-valued age.  
The scaled masses (in grams) of seven different organs and the absolute difference 
compared with ICRP 89 reported masses are listed in Table 6 for all the discrete-age scaling. 
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For all cases, the masses of the brain, pancreas, and kidneys of the scaled phantom were 
smaller than their ICRP 89 counterparts, as indicated by negative differences. However, the 
masses of the scaled lungs and stomach were larger than those in the ICRP 89 data. Lastly, 
except for the 1-year-old phantom, the masses of the scaled heart and liver were smaller 
than those of the ICRP 89 phantoms. Overall, we obtained an absolute difference ranging 
from 0.4g to 340g across all of the studied organs and ages. 
 
Figure 11: Trend of standing heights of scaled phantoms with respect to original UF/NCI 







Table 5. Comparison of standing heights of scaled phantom heights with ground-truth UF/NCI 
phantom heights and with CDC reported 50th percentile heights 
 Scaled Heights (cm) Percent Difference (%) 
Age** Male Female 
UF/NCI 
Male*  







1 (5) 76.2 76.2 0.4 (0.3) 0.4 (0.3) 0.1 (0.1) 2.4 (1.8) 
5 (10) 110.6 110.6 0.3 (0.3) 0.3 (0.3) 1.3 (1.4) 3.0 (3.2) 
10 (15) 139.9 136.0 0.0 (0.0) 2.8 (3.9) 0.8 (1.1) 1.3 (1.8) 
15 (Adult) 169.5 158.9 0.3 (0.5) 1.9 (3.0) 0.1 (0.2) 1.8 (2.8) 
Continuous-valued ages † 
3.9 (5) 102.6 102.6 6.3 (6.9) 5.5 (5.9) 1.1 (1.2) 2.7 (2.7) 
8 (10) 128.3 128.3 4.5 (6.0) 2.8 (3.7) 0.1 (0.2) 0.4 (0.5) 
9.1 (10) 134.8 134.8 3.2 (4.5) 1.4 (1.9) 0.5 (0.6) 1.0 (1.3) 
*Absolute difference is shown in the parenthesis (in cm). **Original age of the phantom that 
was used for downscaling is shown in parenthesis i.  †Power law fit was used to estimate the 




Table 6: Comparison of scaled organ masses of UF/NCI computational phantoms with ICRP 89 reference masses.Scaled masses and 
difference between the scaled and ICRP 89 reference masses are reported. All masses are in grams. 
1-year-old 5-year-old 10-year-old 15-year-old 
  SM SF SM-ICM SF-ICF SM SF SM-ICM SF-ICF SM SF SM-ICM SF-ICF SM SF SM-ICM SF-ICF 
Brain 896.1 896.3 -53.9 -53.7 1158.0 1158.1 -152.0 -21.9 1311.5 1199.5 -88.5 -20.5 1326.7 1196.7 -93.3 -103.3 
Heart 125.3 125.3 27.3 27.3 198.4 198.5 -21.6 -21.5 356.0 291.8 -14.0 -78.2 636.4 469.4 -23.6 -70.6 
Lungs 106.9 106.9 26.9 26.9 174.3 174.2 49.3 49.2 373.7 357.2 163.7 147.2 669.1 547.9 339.1 257.9 
Liver 330.6 330.7 0.6 0.7 451.0 451.2 -119.0 -118.8 714.0 717.1 -116.0 -112.9 1391.5 1082.5 91.5 -217.5 
Stomach 77.0 76.9 57.0 56.9 110.0 110.0 60.0 60.0 170.1 175.2 50.1 55.2 306.4 285.7 156.4 145.7 
Pancreas 19.6 19.6 -0.4 -0.4 31.4 31.4 -3.6 -3.6 57.5 54.4 -2.5 -5.6 105.2 91.1 -4.8 -8.9 
Kidneys 65.7 65.7 -4.3 -4.3 101.3 101.2 -8.7 -8.8 140.9 135.8 -39.1 -44.2 242.1 216.5 -7.9 -23.5 





3.4 Comparison of Wilms’ tumor RT plan dose of exact age-scaled and nearest age-matched 
phantoms 
The results of the dosimetric study, in which the same field size and same isocenter were 
used for the Wilms’ tumor treatment plans for a 3.9-year-old downscaled from a reference 
size 5-year-old and an original unscaled reference size 5-year-old phantom, are reported in 
Table 7 and Figure 12. The beam’s eye view and isodose washes for the 3.9-year-old are 
shown in 12a and 12c, and those for a 5-year-old are shown in 12b and 12d, respectively. In 
the isodose washes, dose coverage of the organs differed between the 3.9-year-old and the 
5.0-year-old. For example, different fractions of the pancreas and liver are enclosed within 
the 75% isodose line (15 Gy). As a result, the absolute differences in V15 of pancreas and liver 
were 3.52% and 5.98%, respectively (Table 7). Results for all organs and dose metrics are 
listed in table 7.  
Results from the dosimetric study where the field borders relative to anatomical 
landmark were consistent for all phantoms (resulting in different field sizes) are listed in 
Table 8 and illustrated in Figure 13. V15 and mean dose were significantly different between 
exact age-scaled and nearest age-matched phantom in all other organs except for the right 
kidney (target), right colon, and gallbladder. The contralateral kidney was significantly 
different between phantoms in all dose metrics except D95. Similarly, liver and pancreas were 
significantly different in all except D1 and D95, respectively. Figure 13 shows the distribution 
of metrics for selected near beam organs; pancreas, liver, contralateral kidney, and stomach. 






Figure 12: Digitally reconstructed radiograph of a Wilms’ tumor plan for (a) a 3.9-year-old 
downscaled from a reference size 5-year-old and (b) an unscaled reference size 5-year-old. 
Isodose wash for liver, stomach, kidneys, and pancreas of (c) the downscaled and (d) the 
unscaled phantoms for 5% (cyan), 75% (blue), 95% (purple), 100% (yellow), and 110% (red) of 
the prescription dose. Except vertebral bodies, no bones were downscaled. 
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Table 7: Absolute and percent difference between the V15 and mean dose 
from 6MV Wilms’ tumor RT plan  (20 Gy to right kidney) between 
unscaled reference size 5-year-old and 5-year-old downscaled to 3.9-year-
old 
Organs 
V15, in % Mean Dose, Gy 
Abs. diff % diff Abs. diff % diff 
Pancreas 3.52 42.04 0.85 4.25 
Liver 5.98 8.61 1.29 6.45 
Stomach 0.00 0.00 0.11 0.55 






Table 8: Metrics investigated to establish the difference in dose from 6 MV Wilms’ tumor RT plan (20 Gy to right kidney) in between 
3.9-year-old and 5.0-year-old phantoms. Wilcoxon rank sum test was performed to determine if differences were statistically 
significant (p<0.05 is significantly different) 
  V15 (in %) Mean Dose (Gy) D1 (Gy) D95 (Gy) 








  Med. Med. Med. Med. Med. Med. Med. Med. 
Pancreas 16.86 19.55 <0.05 4.40 4.75 <0.05 19.13 19.15 >0.05 0.32 0.33 >0.05 
Liver 66.68 70.71 <0.05 14.38 14.86 <0.05 20.97 21.02 >0.05 1.20 1.32 <0.05 
Lt. Kidney  0.01 0.40 <0.05 1.55 1.78 <0.05 9.31 10.78 <0.05 0.72 0.73 >0.05 
Rt. Kidney 100.00 100.00 >0.05 20.07 20.11 >0.05 20.62 20.68 >0.05 19.60 19.62 >0.05 
Rt. Colon 68.08 67.63 >0.05 14.66 14.60 >0.05 21.29 21.35 >0.05 0.59 0.58 >0.05 
Lt. Colon 15.30 15.90 <0.05 4.14 4.36 <0.05 19.76 19.84 >0.05 0.30 0.30 >0.05 
Stomach 0.44 0.59 <0.05 0.87 0.99 <0.05 7.59 9.56 <0.05 0.29 0.30 >0.05 
Gallbladder 100.00 100.00 >0.05 19.78 19.80 >0.05 20.00 20.03 <0.05 19.57 19.58 >0.05 
T. Vertebra 14.29 15.50 <0.05 3.08 3.37 <0.05 19.32 19.35 >0.05 0.00 0.00 <0.05 
L. Vertebra 97.81 98.47 <0.05 18.96 19.04 <0.05 19.95 20.00 >0.05 17.29 17.50 >0.05 
V15 = percent of volume receiving ≥ 15Gy; D1 is dose received by 1% of the volume; D95 is dose received by 95% of the volume. Blue label highlights the significantly different cases; Rt. and Lt. colon 





Figure 13: Boxplot showing the V15, mean dose, D1, and D50 for pancreas, liver, left kidney, 
and stomach. All of the results presented here are significantly different (p<0.05, N=17) 
except D95 for left kidney, D1 for the liver, and D95 for the stomach. Mean is represented by 




4. Discussion  
In this study, we have successfully scaled the realistic CT-based UF/NCI pediatric 
reference phantom to arbitrary ages using our ASFs, which is also a proof-of-concept that our 
ASFs can be used to accurately scale any CT-based anatomy. We have also established that 
dose to organs in between the cohorts of age-specific (continuous-valued age) and nearest 
discrete age-matched phantoms varies significantly (p<0.05). This is an indication that using 
an exact age-scaled phantom is an important consideration for dose reconstruction studies. 
Our ASFs are functions of age, direction and body region, and are primarily used in 
retrospective organ dose reconstruction studies where phantom or patient’s anatomy must 
be generated at the time of RT. Currently, there exists a different types of protocols for 
selecting phantom as surrogate anatomy: one would select phantom by matching the heights 
and weights of the patient or select the nearest age phantom or select the phantom based on 
the anthropometric parameter of the trunk from the CT scan at the time of treatment 
(Whalen et al 2008, Kuzmin et al 2018). However, for retrospective studies such as in the 
CCSS (N>13000 with RT) where patients were treated in the pre-CT era, age is the only most 
common, and often the only anthropometric parameter that is available retrospectively. In 
such a many case, matching the height and weight of the phantom or matching the 
anthropometric parameter of the trunk is not feasible. One would attempt to select a 
nearest-age phantom instead of a continuous-valued age phantom; however, such protocols 
are associated with higher uncertainties in organ shape and size/volume, that can translate 
to uncertainty in organ dose reconstruction and hence in risk assessment (Kry et al 2007, 
Whalen et al 2008, Morton et al 2013). Our age scaling methodologies overcome these 
limitations as they can accurately scale any phantom of choice or CT-based anatomy to the 
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patient’s age at the time of treatment. Furthermore, our ASFs roughly require 3 minutes to 
scale a phantom in TPS which also ensures it suitability in the large cohorts. Lastly, our ASFs 
have been used to scale our in-house phantoms for other cohorts such as the St. Jude 
Lifetime, Adult Life after Childhood Cancer in Scandinavia, and the Dutch Childhood Oncology 
Group over three-decade (listed in Howell et al (2019)).  
Our feasibility study showed reasonable accuracy in the context of overlap and 
displacement metrics for the whole body and various organs. While the whole-body and 
brain showed the best DSC scores, the heart and liver scores were still acceptable as they 
showed median DSCs of 0.69 and 0.73, respectively which means 50% of the distribution are 
>0.7 which is considered a good DSC values (Dice 1945, Zou et al 2004). As reported in 
section 3.2, the pancreas and kidneys showed poor DSC agreement as the median DSCs were 
at 0.32 and 0.58, respectively, but this cannot be solely attributed to an error in 
transformation and scaling as the heart and liver should have also shown poor agreement 
because all organs in trunk use same scaling factors. It is important to note that the UF/NCI 
phantoms at different ages are not from the same/single patient, which introduces inter-
patient variation in  in organ shape, size, and position (Lee et al 2010). Furthermore, another 
reason could be attributed to the sensitivity of DSC to the volume of the organ. For example, 
a 1 cm displacement could affect the pancreas/kidneys more than the brain which has a 
larger volume. The large ED for the liver and pancreas in our study was not unexpected as 
studies of adult patients have reported high range of motion for these organs. One study 
reported motion of up to 5.7 cm in the liver (Davies et al 1994, Langen and Jones 2001), while 
another study reported motion of up to 8 cm in liver and pancreas (Suramo et al 1984, 
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Langen and Jones 2001). This organ displacement also contributed to the poor agreement we 
observed in DSC and MDA.    
In the anthropometric assessment of scaled phantoms, the scaled standing heights 
agreed within 6.3% (6.9 cm) of the reference data. Higher disagreements data were confined 
to continuous-valued ages, likely because we used a power law to interpolate the heights of 
the UF/NCI phantoms at discrete ages to obtain heights at continuous-valued ages. With 
regard to organ masses, we observed ICRP 89 masses were greater than scaled organ masses 
except for the stomach and lungs, where ICRP 89 is smaller. Although the scaled masses 
highly deviated from the ICRP 89 masses, the scaled masses for organs such as the brain, 
lungs, liver, and kidneys for 1-, 5-, and 10-year-old are well within the range of masses 
reported in the US population autopsy study by Molina et al (2019).  
For the dose study, our investigation using the same field size on exact age-scaled versus 
nearest age-matched phantoms showed differences in V15 and mean dose up to 6% and 1.3 
Gy (6.45%), respectively. We used the same field size because, in retrospective dose 
reconstruction, one would not modify the original field size when using an age-matched 
phantom instead of an exact-age phantom. The reason behind the differences is mostly the 
shape and position of the organs which varied across exact age-scaled and nearest age-
matched phantom. In dose reconstruction studies, it has been found that organ shape, 
volume, position, dose reconstruction method, irradiation sources, etc. are the major sources 
of uncertainty in dose estimation. Furthermore, Kry et al (2007) estimated that a 50% 
uncertainty in dose estimation could result in a significant difference in risk of a second 
cancer. Therefore, an uncertainty of 6% in V15 or 6.45% in mean dose can potentially affect 
the risk estimation studies when they are combined with other sources of uncertainties. 
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Additionally, a difference of 1.3 Gy can also affect the risk estimation study if the doses are 
finely binned and organ dose values (not the difference) falls at the edge of the bin. Those 
impacts will be pronounced when the cohort size is large.    Furthermore, it is also important 
to determine the effect of scaling on the field size and hence on the organ dose. Our second 
study showed that V15 and mean dose were significantly different (p<0.05) except for the 
organs that are fully inside the beam. This result was expected because those organs received 
roughly 100% of the prescribed dose in each case.  
While we have successfully demonstrated the feasibility of scaling the phantoms to any 
arbitrary age using our in-house ASFs and have established the difference in dose between 
exact-age and nearest age-matched phantoms, our study also revealed that our ASFs need 
enhancements. Specifically, in the current study, the underestimation and overestimation of 
the organ masses (as shown in Table 6) suggest our ASFs could be enhanced with organ-
specific ASFs in addition to our current body region-specific ASFs. However, it is worthwhile 
to highlight that the scaled masses fell within the range of autopsy masses as discussed 
earlier.  
Our current ASF-related enhancement includes the development of scaling factors based 
on the percentile height of the U.S. population. We are combining our ASFs and CDC-
reported percentile specific-heights to generate percentile specific ASFs. This will allow us to 
scale the phantom based on these heights, which will be available in modern CCSS cohorts. 
For modern cohorts in the CCSS, the survivor data will be present in the CT scans, where we 
can measure body region-specific parameters such as size, volume, and circumference. We 
can use those parameters to estimate the BMI of the patients and develop modulation 
factors to generate cohort-specific ASFs. Finally, our group is enhancing/developing individual 
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organs (e.g. heart, colon, etc.) within our in-house phantom, which involves the incorporation 
of modulation factors into scaling methodologies. For example, Shrestha et al (2020) 
introduced a modulation factor based on inherent differences in the trunk size of a UF/NCI 
phantom and an MDA phantom to develop a new CT-based hybrid heart before integrating it 
into the generic phantom.  
5. Conclusion 
We have successfully implemented our ASFs to scale UF/NCI phantoms from one age to 
another age and have validated the scaling process with reasonable accuracy in terms of 
geometric and anthropometric parameters. We have also established that there exists a 
significant difference in dose to organ between populations of exact age-scaled continuous-
valued phantoms and nearest age-matched discrete aged phantoms. The implementation and 
validation allow us to scale - UF/NCI phantoms or any CT-based patient anatomy for RT 




Chapter 5: Discussions and Conclusion 
1. General Overview 
The primary purpose of this thesis was to implement our FORTRAN phantom and its 
ASFs in DICOM format within a commercial TPS so that our dose reconstruction methods can 
be used to estimate organ doses of survivors treated with contemporary RT plans. Our 
central hypothesis was to implement the phantom within 3% of the FORTRAN phantom with 
scaled heights within 7% of the CDC reported 50th percentile heights. To achieve our purpose, 
we established two specific aims, all of which were successfully completed by developing 
several Python scripts in RayStation TPS.  
Our first aim was to accurately model and validate our computational phantom and 
its ASFs in DICOM format. We validated our implementation by calculating percent 
differences in corner points, volume, and scaled heights of the DICOM phantom and 
reference data. All of the metrics were well within limits set in our central hypothesis. Most 
of the discrepancies in modeling were attributed to the removal of the negligible gap present 
in between the body regions of our generic phantom. The conversion of our organs from 
point form to surface contours enabled us to estimate dose to organ ROIs for the first time. 
Our dose metrics for partially in-beam organs from TPS agreed within 0.07Gy (mean dose) of 
the results from the fully validated in-house dose calculation method. That supported our 
hypothesis that our phantom is ready to be used for dose calculation studies within a TPS. 
The validation of our ASFs in aim 1 inspired us to scale other whole-body CT-based 
phantoms using our age-scaling methodologies. We adopted UF/NCI phantoms to test the 
feasibility and successfully scaled the phantoms to arbitrary ages using our ASFs. To assess 
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the dosimetric impact of scaling, we designed a study in which we constructed standard 
Wilms’ tumor plan of a CCS on an exact age-scaled phantom and the nearest age-matched 
phantom. The phantom selection based on a nearest anthropometric parameter such as age 
is pretty standard when the exact age phantom is unavailable. Our study showed this could 
lead to uncertainty in dose metrics such as up to 6% and 1.3Gy in V15 and mean dose, 
respectively, when field size was kept the same between the two phantom types. Since the 
risk-assessment studies report doses in bins, a difference of 6% or 1.3Gy alone could not 
affect the risk-assessment results. However, the dose-reconstruction methodologies include 
uncertainties due to various sources, as reported in Vũ Bezin et al (2017) and Xu et al (2008). 
Therefore, a 6% uncertainty in combination with other sources could exceed a total 
uncertainty of 50%, which has been estimated to affect risk-assessment studies significantly 
(Kry et al 2007, Vũ Bezin et al 2017).   
2. Project Limitation and Future Directions 
A retrospective analysis of our two aims revealed several aspects of projects that can 
be improved. First, in aim one and aim 2, we found that the scaled organ masses were 
smaller than the masses from reference phantoms and autopsy. In aim 2, most of the 
discrepancies in height were confined to female data. Such discrepancies could be improved 
if we have ASFs specific to the population's organ, sex, and percentile height.  A preliminary 
study has already been conducted to develop percentile-specific ASFs. We modified our ASFs 
in AP, IS, and RL by using modulation factors that would match the scaled heights of the 
phantom to CDC-reported percentile-specific heights at discrete ages. Figure 14 and 15 shows 


















Figure 15: Change in the volume (volume is shown in white) of heart, liver, and colon (test 
model) as a percentile-based ASF function is shown for 5-year-old. 
Another project that we would like to work on is the use of ASFs to scale ICRP 143 
pediatric reference phantom. ICRP 143 adopted the reference size UF/NCI phantom, which 
makes the phantom standard for use in dosimetry studies. Several modifications, such as the 
development of organ substructures, the addition of lymph nodes, and overall enhancement, 
were performed before ICRP adopted this phantom. A visual comparison between two 
phantoms at five years of age is shown in Figure 16, which shows the advancement of 
anatomy. Therefore, using ASFs to scale the organs with substructure will be a new addition 






Figure 16: Comparison of a 5-year-old ICRP 143 and UF/NCI male and female phantoms 
(armless version) 
Another major study that our group would like to calculate the accuracy of out-of-
field dose in the RayStation treatment planning system. Such studies are essential because, 
for late effects studies, near beam and far beam organs are of significant interest and TPS are 
not accurate for those organs. The quantification of accuracy will allow us to incorporate 
modulation factors in our dose-reconstruction method for cohorts treated with 
contemporary RT. A previous study from our group was conducted for Pinnacle TPS when 




Our results show that we have accurately implemented our computational phantom 
and its ASFs in the DICOM format. The phantom and ASFs can be used for dose calculation of 
studies. We have also validated that our ASFs can be used to scale whole-body CT-based 
anatomy. One major recommendation that this thesis project suggests is using exact age-
scaled phantom over nearest matched phantom in dose reconstruction studies is an 














Appendix A: Mathematical calculations showing transformation of our generic phantom to 
7.0-year-old phantom 
This appendix is obtained from the following peer-reviewed publication: 
A.C. Gupta, S. Shrestha, C.A. Owens, S.A. Smith, Y. Qiao, R.E. Weathers., P.A. Balter, S.F. Kry, 
and R.M. Howell, “Development of an age-scalable 3D computational phantom in DICOM 
standard for late effects studies of childhood cancer survivors,” Biomedical Physics and 
Engineering Express. Volume 6, Issue 6, pages 1-15. © IOP Publishing Ltd. 
This work is licensed under a Creative Commons Attribution 4.0 license. It is attributed to 
Aashish C. Gupta, Suman Shrestha, Constance A. Owens, Susan A. Smith, Ying Qiao, Rita E. 
Weathers., Peter A. Balter, Stephen F. Kry, and Rebecca M. Howell, and the original version 
can be found here. 
 
We present a sample calculation following the steps in Figure 3 to illustrate how our 
generic “adult” phantom is transformed to a 7.0-year-old phantom. Due to the symmetric 
nature of a cube, if two corner points describing a diagonal of the cube are known, then we 
can calculate the remaining six corner points of the cube. Hence, we only present the 
transformation of two opposite corner points for each of the phantom’s cuboidal body 
regions. Additionally, we illustrate the transformation of one point in an organ within the 
trunk body region.  
Step 1: Import Data 
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In this step, we import the organ points and corner points of the body region from the 
FORTRAN generic phantom into a DICOM file present in RayStation. To begin, pr and qr 
represent the two opposite corners of the cube. Here r ϵ {upper head (uh), lower head (lh), 
neck (n), trunk (tr), arms (ar), legs (lg)}. The body regions with their opposite corner points 
are presented in the table below.  
Table 9: Opposite corner points describing the main diagonal of each 
body region in the generic phantom. The corner points are scaled and 
translated using equations (1) through (6) to obtain the phantom of 
age 𝐚. 
Head (upper and 
lower) 
puh(−2.30, 1.00, 0.00) and qlh(2.30, 6.70, 4.80) 
Neck pn(−1.20, 6.70, 1.10) and qn(1.20, 7.60, 3.50) 
Trunk ptr(−4.00, 7.60, 0.10) and qtr(4.00, 24.00,
4.90) 
Leg plg(−2.80, 24.00, 1.10) and qlg(2.80, 43.20, 3.60) 
Arm* par(4.00, 8.00, 1.60) and qar(5.60, 21.60, 3.20) 
* In table 9, we present the calculation for the right arm only due to 
symmetry in approach. 
To illustrate how organ points are transformed, we chose the point (-3.40, 14.30, 2.60) in the 
liver.  
Step 2: Select Phantom Age 
Here, we select the age of the phantom as 7.0 years. 
Step 3: Transform Coordinates 
Based on the user-specified age, we use equations (1) through (6) to transform the points 
of the generic phantom to a phantom of age 7.0 years. The process can be divided into two 




In phase (i), we identify the age group and access the preloaded scaling factor data for the 
lower and upper age bounds. Here, the age of 7.0 years falls within the category [5, 10). To 
calculate the scaling factor for 7.0 years, we use equation (2), which requires the scaling 
factors for upper and lower age bounds (a−). The scaling factors corresponding to a− = 5.0 
and a+ = 10.0 for each body region are presented in Table 10.  
Table 10: Scaling factors corresponding to the ages of 5.0 and 10.0 
years are shown as age=7.0 𝝐 [5.0,10.0) 
 Age = 5.0 Age = 10.0 
 (LR (x), SI (y), AP (z))* (LR (x), SI (y), AP (z))* 
Head (3.022, 3.286, 3.872) (3.130, 3.464, 3.957) 
Neck (3.292, 3.026, 3.292) (3.500, 3.410, 3.500) 
Trunk (2.250, 2.442, 2.653) (2.750, 3.018, 3.163) 
Leg (3.750, 2.474, 3.840) (4.583, 3.411, 5.120) 
Arm (3.125, 2.647, 3.125) (4.000, 3.493, 4.000) 
*LR=Left to Right, SI=Superior to Inferior, AP=Anterior to Posterior directions 
𝐅𝐜𝐨𝐧𝐭(𝐱, 𝐮𝐡, 𝟕) = 𝐅𝐝𝐢𝐬(𝐱, 𝐮𝐡, 𝟓) +
𝟕. 𝟎 − 𝟓. 𝟎
𝟏𝟎. 𝟎 − 𝟓. 𝟎 
(𝐅𝐝𝐢𝐬(𝐱, 𝐮𝐡, 𝟏𝟎) −  𝐅𝐝𝐢𝐬(𝐱, 𝐮𝐡, 𝟓)) 
 
Fcont(x, uh, 7) = 3.022 +
7.0 − 5.0
10.0 − 5.0 
(3.130 − 3.022)  = 3.065  
 
The above calculation is repeated in all three directions for each body region, and we finally 
obtain all scaling factors for age 7.0 years (Table 11). For the organ points, the same 





Table 11: Scaling factors for each body region to scale the 
phantom from generic to age 7.0 years 
 (𝐋𝐑 (𝐱), 𝐒𝐈 (𝐲), 𝐀𝐏 (𝐳)) ∗ 
Head (3.065, 3.357, 3.906) 
Neck (3.375, 3.180, 3.375) 
Trunk (2.450, 2.672, 2.857) 
Leg (4.083, 2.849, 4.352) 
Arm (3.475, 2.985, 3.475) 
*LR=Left to Right, SI=Superior to Inferior, AP=Anterior to Posterior directions 
In phase (ii), the body region corner points and the organ points are transformed using 
equations (3) and (6). The transformation of each body region is shown in the subsections 
below. 
Transformation of the head corner points: 
For puh(−2.30, 1.00, 0.00):  
xt =  x ⋅ Fcont(x, r, a) = −2.30 ⋅ 3.065 = −7.05 cm  
yt = ∑ luh
uh
r=uh
⋅ Fcont(y, uh, 7)    = (y − ysbr) ⋅ Fcont(y, uh, 7) = (1.00 − 1.00) ⋅ 3.357
= 0.00 cm 
zshift  =  
Zhead ⋅ F(z, uh, 7) − Zhead ⋅ F(z, uh, 7)
2
= 0.00 




For quh(2.30, 6.70, 4.80): 
xt =  2.30 ⋅ 3.065 = 7.05 cm  
yt = (yibruh − ysbruh) ⋅ Fcont(y, uh, 7) + (y − yibruh) ⋅ Fcont(y, n, 7)
= (3.80 − 1.00) ⋅ 3.357 + (6.70 − 3.80) ⋅ 3.180 = 18.62 cm 
zshift  =  
Zhead ⋅ F(z, uh, 7) − Zhead ⋅ F(z, uh, 7)
2
= 0.00 
zt =  4.80 ⋅ 3.906 = 18.75 cm 
Transformation of the neck corner points: 
For pn(−1.20, 6.70, 1.10): 
xt =  −1.20 ⋅ 3.375 = −4.05 cm  
 
Since the superior boundary of the neck on the y-axis is the same as the inferior boundary of 
the lower head, the transformed point is the same as that obtained for the lower boundary of 
the head on the y-axis.  
zshift  =  
Zhead ⋅ F(z, uh, a) − Zn ⋅ F(z, n, a)
2
=
(4.70 − 0.00) ⋅ 3.906 − (3.50 − 1.10) ⋅ 3.375
2
  
= 5.13 cm                                              
zt = (1.10 − 1.10) ⋅ 3.375 + 5.13 = 5.13 cm 
For qn(1.20, 7.60, 3.50): 
xt =  1.20 ⋅ 3.375 = 4.05 cm 
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yt = (yibruh − ysbruh) ⋅ Fcont(y, uh, 7) + (yibrlh − ysbrlh) ⋅ Fcont(y, n, 7) + (y − ysbrn)
⋅ Fcont(y, n, 7)  
= (3.80 − 1.00) ⋅ 3.357 + (6.70 − 3.80) ⋅ 3.180 + (7.60 − 6.70) ⋅ 3.180
= 21.48 cm 
zt = (3.50 − 1.10) ⋅ 3.375 + 5.13 = 13.23 cm 
 
Transformation of the trunk corner points: 
For ptr(−4.00, 7.60, 0.10): 
xt =  −4.00 ⋅ 2.450 = −9.80 cm 
yt = 21.48 cm 
Zshift =  
4.70 ⋅ 3.906 − 4.90 ⋅ 2.857
2
= 2.18 cm 
zt = (0.10 − 0.10) ⋅ 2.857 + 2.18 = 2.18 cm 
For qtr(4.00, 24.00, 4.90): 
xt =  4.00 ⋅ 2.450 = 9.80 cm 
yt = (yibruh − ysbruh) ⋅ Fcont(y, uh, 7) + (yibrlh − ysbrlh) ⋅ Fcont(y, n, 7) +  (yibrn − ysbrn)
⋅ Fcont(y, n, 7) + (y − ysbrtr) ⋅ Fcont(y, tr, 7)
= (3.80 − 1.00) ⋅ 3.357 + (6.70 − 3.80) ⋅ 3.180 + (7.60 − 6.70) ⋅ 3.180
+ (24.00 − 7.60) ⋅ 2.672 = 65.30 cm 
zt = (4.90 − 0.10) ⋅ 2.857 + 2.18 = 15.89 cm 
 
Transformation of the leg corner points: 
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For plg(−2.80, 24.00, 1.10) and qlg(2.80, 43.20, 3.60):  
The transformed x- and z-coordinates of the leg volume are the same as the transformed 
x- and z-coordinates of the trunk. This was done because we have one leg volume in the 
phantom. To prevent the leg volume lying outside the xz plane of the trunk when the 
phantom is scaled to higher ages, we used the same scaling in the xz direction as for the 
trunk. The length of the leg in the y direction is calculated using equation (4). 
For plg(−2.8, 24.0, 1.1): 
yt = 65.30 cm 
For qlg(2.80, 43.2, 3.60):  
yt = (yibruh − ysbruh) ⋅ Fcont(y, uh, 7) + (yibrlh − ysbrlh) ⋅ Fcont(y, n, 7) +  (yibrn − ysbrn)
⋅ Fcont(y, n, 7) +  (yibrtr − ysbrtr) ⋅ Fcont(y, tr, 7) + (y − ysbrlg )
⋅ Fcont(y, lg, 7)
= (3.80 − 1.00) ⋅ 3.357 + (6.70 − 3.80) ⋅ 3.180 + (7.60 − 6.70) ⋅ 3.180
+ (24.00 − 7.60) ⋅ 2.672 + (43.20 − 24.00) ⋅ 2.894 =  120.01 cm  
 
Transformation of the arm corner points: 
For par(4.00, 8.00, 1.60): 
On the x-axis, the arm starts at the same x-coordinate at which the trunk volume ends. Thus, 
xt = 9.80 cm. On the y-axis, the volume starts at the same y-coordinate as the trunk. 
84 
 
zt = (1.60 − 1.60) +
(4.70 − 0.00) ⋅ 3.906 − (3.20 − 1.60) ⋅ 3.475
2
= 6.40 cm 
For qar(5.60, 21.60, 3.20): 
xt = 5.60 ⋅ 3.475 = 19.46 cm 
yt = (yibruh − ysbruh) ⋅ Fcont(y, uh, 7) + (yibrlh − ysbrlh) ⋅ Fcont(y, n, 7) +  (yibrn − ysbrn)
⋅ Fcont(y, n, 7) + (y − ysbrar) ⋅ Fcont(y, ar, 7)
= (3.80 − 1.00) ⋅ 3.357 + (6.70 − 3.80) ⋅ 3.180 + (7.60 − 6.70) ⋅ 3.180
+ (21.60 − 8.00) ⋅ 2.985 = 62.08 cm 
zt = (3.20 − 1.60) ⋅ 3.475 + 6.40 = 11.96 cm 
 
Transformation of organ points: 
The scaling and translation of organs is performed in the same way as the body regions in 
which they are located. For example, we present here the scaling of one of the points of the 
liver, which is present in the trunk region. The sample calculation for the point (-3.40, 14.30, 
2.60) in the liver is shown below: 
xt = −3.40 ⋅ 2.450 = −8.33 cm 
yt = (3.80 − 1.00) ⋅ 3.357 + (6.70 − 3.80) ⋅ 3.180 + (7.60 − 6.70) ⋅ 3.180
+ (14.30 − 7.60) ⋅ 2.672 = 39.39 cm  
zt = (2.60 − 0.10) ⋅ 2.857 +
4.70 ⋅ 3.906 − 4.90 ⋅ 2.857
2
= 9.32 cm 
Hence, the transformed point of the liver is (-8.33, 39.39, 9.32).  
Step 4: Reorient Phantom 
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To model the phantom in the treatment planning system, we reorient our phantom to 
head-first, supine (HFS). Thus, the y- and z-coordinates are reversed. This results in the 
patient’s left to right orientation toward –x direction, superior to inferior orientation toward 
–z direction, and anterior to posterior orientation toward +y direction. An example of the 
calculated point of the liver in HFS orientation is presented below. 
(-8.33, 39.39, 9.32) y and z are flipped 
 
(-8.33, 9.32, -39.39) 
All organ points and body region corner points are reoriented in the same manner. 
Steps 5, 6, and 7: Convert Body Regions and Organs to ROI/DICOM format and Plot 
Phantom in RayStation 
After the data are oriented in the HFS coordinate system, each body region is converted 
from a collection of points to ROI format. Likewise, the collection of points representing an 
organ is converted to ROI format. Next, the body regions and organs are plotted in 
RayStation. RayStation allows users to export the phantom in DICOM format, which can be 




Appendix B: Scaling of any computational phantom using graphical user interface (GUI) 
surface in RayStation TPS 
We have developed a Graphical User Interface (GUI) application in RayStation TPS, 
which can scale whole-body CT-based anatomy to any arbitrary ages using our ASF. While the 
latest version of the GUI is discussed here, several modifications will be made soon to 
accommodate the need for various phantoms and patient scans. The GUI has five tabs, each 
of which is independent of one another. All of the scaling are performed in the ‘Patient 
Import, and Scaling’ tab described below (shown in Figure 17). 
The user first imports the phantom and then performs the scaling. In the import 
panel, age, type of phantom (MDA, UC/NCI, and ICRP (when implemented)), and sex can be 
specified to import phantoms from our structure template library in the TPS. This particular 
step is not required if the user has already imported anatomy through DICOM import 
functions. In the scaling panel, the user specifies the current age of the phantom and then 
the final target age of the phantom. The user can further select the type of scaling from the 
following options: MDA Main, 5th, 25th, 50th, 75th, 95th, and 99th percentile.  The scaling 
performed here is very fast as the time required to scale 5 body regions and 52 organs is 
roughly 1.80 minutes. If we combine that time with the time required to import structures, 
the total time is roughly 3 minutes.  
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